Bibliografie 2

Referinţe
1. Drake R, Wayne Vogl A, Mitchell A, Gray´s Anatomy for Students, 2nd Edition, Churchill
Livingstone, 2009.
2. Mills SE (editor), Histology for Pathologists, third edition. Lippincott Williams & Wilkins,
Philadelphia, 2007.
3. Day DW, Jass JR, Price AB, et al, (editors), Morson and Dawson’s Gastrointestinal
Pathology, Blackwell Publishing, 2003.
4. Banks, P. M. (2007), Gastrointestinal lymphoproliferative disorders. Histopathology, 50:
42–54.
5. Anita Annaházi, Tamás Molnár (2014), Pathogenesis of Ulcerative Colitis and Crohn’s
Disease: Similarities, Differences and a Lot of Things We Do Not Know Yet J Clin Cell
Immunol 2014,5:4.
6. DiMarino, Anthony J; Coben, Robert M; Infantolino, Anthony; Sleisenger, Marvin H,
Sleisenger and Fordtran's gastrointestinal and liver disease: review and assessment, 9th ed.,
Philadelphia, PA : Saunders/Elsevier, 2010.
7. Nascimbeni, R., Fabio, F. D., Betta, E. D., Mariani, P., Fisogni, S., & Villanacci, V.
(2005). Morphology of colorectal lymphoid aggregates in cancer, diverticular and
inflammatory bowel diseases. Modern Pathology, 18(5), 681-5.
8. Levine D.S., Haggitt R.C. Normal histology of the colon. Am. J. Surg. Pathol.
1989;13:966–84
9. Kenneth Saladin, Anatomy and Physiology -- The Unity of Form and Function, William C.
Brown, 1997.
10. Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012).
Ulcerative colitis. The Lancet, 380(9853), 1606-19.
11. Farrell, R. J., & Peppercorn, M. A. (2002). Ulcerative colitis. The Lancet, 359(9303),
331-40.
12. Odze, R. (2013). IBD role of the pathologist in the diagnosis and management of IBD.
Nature Reviews Gastroenterology & Hepatology, 10(11), 625-626.
13. Bamias, G., Nyce, M. R., Sarah A De La, R., & Cominelli, F. (2005). New concepts in
the pathophysiology of inflammatory bowel disease. Annals of Internal Medicine, 143(12),
895-904.
14. Silvio Danese, and Claudio Fiocchi, (2011) Ulcerative Colitis, Engl J Med; 365:1713-
1725.
15. (2004), Mayo clinic gastroenterology and hepatology board review. Hepatology, 39:
1182.
16. Odze, R., Goldblum, J., Crawford, J., (2003), Surgical Pathology of the GI Tract, Liver,
Biliary Tract, and Pancreas, Saunders W.B..
17. Michael D. Kappelman, Kristen R. Moore, Jeffery K. Allen, Suzanne F. Cook, (2013),
Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially
Insured US Population, Digestive Diseases and Sciences, Volume 58, Issue 2, pp 519-525.
18. Danese S, Sans M, Fiocchi C. (2004), Inflammatory bowel disease: the role of
environmental factors. Autoimmun Rev;3:394-400.
19. Natalie A. Molodecky, Ing Shian Soon, Doreen M. Rabi, William A. Ghali, Mollie Ferris,
Greg Chernoff, Eric I. Benchimol, Remo Panaccione, Subrata Ghosh, Herman W. Barkema,
Gilaad G. Kaplan (2012), Increasing Incidence and Prevalence of the Inflammatory Bowel
Diseases With Time, Based on Systematic Review; Gastroenterology. 142(1):46-54.
20. Hou JK, El-Serag H, Thirumurthi S. (2009), Distribution and manifestations of
inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic
review. Am J Gastroenterol;104:2100–2109.
21. Bernstein CN, Shanahan F. (2008), Disorders of a modern lifestyle: reconciling the
epidemiology of inflammatory bowel diseases. Gut;57:1185–1191.
22. Ha, Christina,Katz, Seymour. (2013). IBD: Elderly-onset IBD: A milder disease? Nature
Reviews Gastroenterology and Hepatology, 10(5), 264-265.
23. Ruel, J., Ha, C., Charpentier, C., Gower-Rousseau, C., & Colombel, J. (2013). IBD in the
elderly. Inflammatory Bowel Disease Monitor, 14(1), 1-11.
24. Loftus EV Jr. (2004), Clinical epidemiology of inflammatory bowel disease: incidence,
prevalence, and environmental influences. Gastroenterology;126:1504-1517.
25. Stonnington, C.M, Phillips, S.F, Melton III, L.J,Zinsmeister, A.R. (1987). Chronic
ulcerative colitis: Incidence and prevalence in a community. Gut, 28(4), 402-409.
26 Loftus EV Jr, Sandborn WJ, (2002). Epidemiology of inflammatory bowel disease .
Gastroenterol Clin North Am 31 1-20.
27. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V, (1991): Incidence and
prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987 . Scand J
Gastroenterol 26 1247-1256.
28. Greth, J, Török, H.-P, Koenig, A,Folwaczny, Christian. (2004). Comparison of
inflammatory bowel disease at younger and older age. European Journal of Medical
Research, 9(12), 552-554.
29. Ha, Christina Y, Newberry, Rodney D, Stone, Christian D, Ciorba, Matthew A. (2010).
Patients with late-adult-onset ulcerative colitis have better outcomes than those with early
onset disease. Clinical Gastroenterology and Hepatology, 8(8), 682-687.
30. El-Tawil, A. M. (2009). Jews and inflammatory bowel diseases. Journal of
Gastrointestinal and Liver Diseases, 18(2), 137-138.
31. Lynch HT1, Brand RE, Locker GY. (2004), Inflammatory bowel disease in Ashkenazi
Jews: implications for familial colorectal cancer, Fam Cancer. 3(3-4):229-32.
32. Sakamoto, N, Okamoto, K, Kobashi, G, Washio, M, Yokoyama, T, Date, C, Tanaka, H,
Kono, S, Wakai, K, Fukuda, Y, Satomi, A, Shimoyama, T, Inaba, Y, Miyake, Y, Sasaki,
S,Epidemiology Grp of the Res Comm. (2005). Dietary risk factors for inflammatory bowel
disease - A multicenter case-control study in japan. Inflammatory Bowel Diseases, 11(2),
154-163.
33. Amre, Devendra K, Deslandres, Colette, Chotard, Virginie, Budai, Balint, Law, Liliane,
Levy, Emile, Seidman, Ernest G, D'Souza, Savio, Morgan, Kenneth, Seidman, Gillian,
Lambrette, Philippe, Grimard, Guy, Israel, David, MacK, David, Ghadirian, Parviz. (2007).
Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with
risk for crohn's disease in children. American Journal of Gastroenterology, 102(9), 2016-
2025.
34. Tragnone, A, Valpiani, D, Miglio, F, Elmi, G, Bazzocchi, G, Pipitone, E, Lanfranchi,
G.A. (1995). Dietary habits as risk factors for inflammatory bowel disease. European Journal
of Gastroenterology and Hepatology, 7(1), 47-51.
35. Calder, P. C. (2009). Fatty acids and immune function: Relevance to inflammatory bowel
diseases. International Reviews of Immunology, 28(6), 506-534.
36. Hart, A. R., Luben, R., Olsen, A., Tjonneland, A., Linseisen, J., Nagel, G., Bingham, S.
(2008). Diet in the aetiology of ulcerative colitis: A european prospective cohort study.
Digestion, 77(1), 57-64.
37. de Silva, Punyanganie, MBBS, MRCP, Lund, E. K., PhD., Chan, Simon, MB BChir,
M.R.C.P., PhD., & Hart, A. R., M.D. (2011). Is diet involved in the etiology of ulcerative
colitis and Crohn's disease? A review of the experimental and epidemiological literature.
Inflammatory Bowel Disease Monitor, 12(1), 14-22.
38. Geerling, B.J, Dagnelie, P.C, Badart-Smook, A, Russel, M.G, Stockbrügger,
R.W,Brummer, R.-J.M. (2000). Diet as a risk factor for the development of ulcerative colitis.
American Journal of Gastroenterology, 95(4), 1008-1013.
39. Reif, S., Klein, I., Lubin, F., Farbstein, M., & al, e. (1997). Pre-illness dietary factors in
inflammatory bowel disease. Gut, 40(6), 754-60.
40. Perl, Daniel P, Fogarty, Ursula, Harpaz, Noam, Sachar,David B. (2004). Bacterial-metal
interactions: The potential role of aluminum and other trace elements in the etiology of
crohn's disease. Inflammatory Bowel Diseases, 10(6), 881-883.
41. Erichsen, Kari, Milde, Anne Marita, Arslan, Gülen, Helgeland, Lars, Gudbrandsen,
Oddrun Anita, Ulvik, Rune J, Berge, Rolf K, Hausken, Trygve,Berstad, Arnold. (2005). Low-
dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced
colitis. Inflammatory Bowel Diseases, 11(8), 744-748.
42. Lerner, A, Eluri, S, Perl, D, Moalem, S, Sachar, D, Tonkonogy, S,Sarior, RB. (2006).
Bacterial-aluminum interactions. the role of aluminum in bacterial-induced colitis in IL-10
deficient mice. Gastroenterology, 130(4), A362-A363
43. Leslie WD, Miller N, Rogala L, Bernstein CN (2008) Vitamin D status and bone density
in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J
Gastroenterol 103: 1451-1459.
44. Jørgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Jens, Dahlerup F,
(2013) Active Crohn's disease is associated with low vitamin D levels. J Crohns Colitis 7:
e407-413.
45. Ramagopalan, Sreeram V, Orton, Sarah-Michelle, Watson, Corey T, Morahan, Julia M,
Giovannoni, Gavin, Ponting, Chris P, Ebers, George C, Knight, Julian C, Heger, Andreas,
Berlanga, Antonio J, Maugeri, Narelle J, Lincoln, Matthew R, Burrell, Amy, Handunnetthi,
Lahiru, Handel, Adam E,Disanto, Giulio. (2010). A ChIP-seq defined genome-wide map of
vitamin D receptor binding: Associations with disease and evolution. Genome Research,
20(10), 1352-1360.
46. Prietl B, Treiber G, Pieber TR, Amrein K (2013) Vitamin D and immune function.
Nutrients 5: 2502-2521.
47. Mouli VP, Ananthakrishnan AN (2014) Review article: vitamin D and inflammatory
bowel diseases. Aliment Pharmacol Ther 39: 125-136.
48. Zhang, Yong, Leung, Donald Y. M, Richers, Brittany N, Liu, Yusen, Remigio, Linda K,
Riches, David W, Goleva, Elena. (2012). Vitamin D inhibits monocyte/macrophage
proinflammatory cytokine production by targeting MAPK phosphatase-1. Journal of
Immunology, 188(5), 2127-2135.
49. Klement, Eyal, Cohen, Regev V, Boxman, Jonathan, Joseph, Aviva,Reif, Shimon. (2004).
Breastfeeding and risk of inflammatory bowel disease: A systematic review with meta-
analysis. The American Journal of Clinical Nutrition, 80(5), 1342-1352.
50. Koletzko, S, Sherman, P, Corey, M, Griffiths, A,Smith, C. (1989). Role of infant feeding
practices in development of Crohn's disease in childhood. British Medical Journal,
298(6688), 1617-1618.
51. Ekbom, A, Adami, H.-O, Helmick, C.G, Jonzon, A,Zack, M.M. (1990). Perinatal risk
factors for inflammatory bowel disease: A case-control study. American Journal of
Epidemiology, 132(6), 1111-1119.
52. Gilat, T, Hacohen, D, Lilos, P,Langman, M.J.S. (1987). Childhood factors in ulcerative
colitis and crohn's disease. an international cooperative study. Scandinavian Journal of
Gastroenterology, 22(8), 1009-1024.
53. Tocchi, A, Lepre, L, Liotta, G, Mazzoni, G, Costa, G, Taborra, L,Miccini, M. (1997).
Familial and psychological risk factors of ulcerative colitis. Italian Journal of
Gastroenterology and Hepatology, 29(5), 395-398.
54. Lerebours, Eric, Colombel, Jean Frederic, Cortot, Antoine, Benichou, Jacques, Gower-
Rousseau, Corinne, Merle, Veronique, Brazier, Franck, Debeugny, Stephane, Marti,
Raymond, Salomez, Jean Louis, Hellot, Marie France, Dupas, Jean Louis. (2007). Stressful
life events as a risk factor for inflammatory bowel disease onset: A population-based case-
control study. American Journal of Gastroenterology, 102(1), 122-131.
55. Levenstein, S, Marcheggiano, A, Prantera, C, Varvo, V, Scribano, ML, Andreoli, A, Luzi,
C, Arca, M, Berto, E, Milite, G. (2000). Stress and exacerbation in ulcerative colitis: A
prospective study of patients enrolled in remission. American Journal Of Gastroenterology,
95(5), 1213-1220.
56. Wahed, M, Goodhand, J, Langmead, L, Irving, PM, Sanderson, JD, Bloom, SL,
McCartney, S, Mawdsley, J,Rampton, DS. (2011). Anxiety and psychological stress in acute
severe ulcerative colitis: Prevalence and effect on outcome. Gastroenterology, 140(5), S60-
S61.
57. Mawdsley, J.E, Rampton, D.S. (2005). Psychological stress in IBD: New insights into
pathogenic and therapeutic implications. Gut, 54(10), 1481-1491.
58. Vlachos II, Barbatis C, Tsopanomichalou M, Abou-Assabeh L, Goumas K, Ginieri-
Coccossis M, Economou M, Papadimitriou GN, Patsouris E, Nicolopoulou-Stamati P.
(2014), Correlation between depression, anxiety, and polymorphonuclear cells' resilience in
ulcerative colitis: the mediating role of heat shock protein 70. BMC Gastroenterol. Apr
17;14:77.
59. Madretsma, Stanley, Wolters, Leonieke M.M, Van Dijk, Jeanette P.M, Tak, Corné J.A.M,
Feyerabend, Colin, Wilson, J.H. Paul, Zijlstra,Freek J. (1996). In-vivo effect of nicotine on
cytokine production by human non-adherent mononuclear cells. European Journal of
Gastroenterology and Hepatology, 8(10), 1017-1020.
60. Bernstein, Charles N, Rawsthorne, Patricia, Cheang, Mary, Blanchard,James F. (2006). A
population-based case control study of potential risk factors for IBD. American Journal of
61. Jones, Deborah T, Osterman, Mark T, Bewtra, Meenakshi, Lewis, James D. (2008),
Passive smoking and inflammatory bowel disease: A meta-analysis, American Journal of
Gastroenterology, vol. 103, no. 9, pp. 2382-2393.
62. Jiang, Li, Liu, Hongying, Xu, Hualin, Cheng, Hong, Yang, Huiying, Xia, Bing, Li, Jin,
Ye, Mei, Deng, Changsheng, Ding, Yijuan, Luo, Hesheng, Ren, Hongyu, Hou, Xiaohua,
(2007), Risk factors for ulcerative colitis in a Chinese population: An age-matched and sex-
matched case-control study, Journal of Clinical Gastroenterology, vol. 41, no. 3, pp. 280-284.
63. Kaplan, Gilaad G, Hubbard, James, Korzenik, Joshua, Sands, Bruce E, Panaccione,
Remo, Ghosh, Subrata, Wheeler, Amanda J, Villeneuve, Paul J., (2010), The inflammatory
bowel diseases and ambient air pollution: A novel association, American Journal of
64. Li X, Sundquist J, Sundquist K., (2009) Educational level and occupation as risk factors
for inflammatory bowel diseases: a nationwide study based on hospitalizations in Sweden.
Inflamm Bowel Dis;15:608-15.
65. Sun, Qinghua, Lippmann, Morton, Chen, Lung Chi, Rajagopalan, Sanjay, Wang, Aixia,
Jin, Ximei, Natanzon, Alex, Duquaine, Damon, Brook, Robert D, Aguinaldo, Juan-Gilberto
S, Fayad, Zahi A,Fuster, Valentin (2005), Long-term air pollution exposure and acceleration
of atherosclerosis and vascular inflammation in an animal model, Journal of the American
Medical Association, vol. 294, no. 23, pp. 3003-3010.
66. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM., (1997), Non-
steroidal anti-inflammatory drugs are associated with emergency admission to hospital for
colitis due to inflammatory bowel disease. Gut; 40: 619-2.
67. Felder, Joseph B, Korelitz, Burton I, Rajapakse, Ramona, Schwarz, Samuel, Horatagis,
Angelo P,Gleim, Gilbert, (2000), Effects of nonsteroidal antiinflammatory drugs on
inflammatory bowel disease: A case-control study, American Journal of Gastroenterology,
vol. 95, no. 8, pp. 1949-1954.
68. Scarpignato, Carmelo, Hunt,Richard H. (2010), Nonsteroidal Antiinflammatory Drug-
Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention,
Gastroenterology clinics of North America, vol. 39, no. 3, pp. 433-464.
69. Chan SS, Hart AR (2011) Aspirin use and development of inflammatory bowel disease:
confounding or causation? authors' reply. Alimen Pharmacol Ther 34: 1351.
70. Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, et al. (2012)
Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative
colitis: a cohort study. Ann Intern Med 156:350-359.
71. Boyko EJ, Theis MK, Vaughan TL, Nicol-Blades B. (1994), Increased risk of
inflammatory bowel disease associated with oral contraceptive use. AmJ Epidemiol, 140:
268-78.
72. Giovanni Corrao, Antonella Tragnone, Renzo Caprilli, Giacomo Trallori, Claudio Papi,
Arnaldo Andreoi, Mariacarla Di Paolo, Gabriele Riegler, Gian-Piero Rigo, Oscar Ferraù,
Carlo Mansi, Marcello Ingrosso, Daniela Valpiani, and Cooperative Investigators of the
Italian Group for the Study of the Colon and the Rectum (GISC), (1998), Risk of
inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in
Italy: a nationwide case-control study, Int. J. Epidemiol. 27 (3): 397-404.
73. Cosnes, Jacques, Gowerrousseau, Corinne, Seksik, Philippe,Cortot, Antoine, (2011),
Epidemiology and natural history of inflammatory bowel diseases, Gastroenterology, vol.
140, no. 6, pp. 1785-1794.
74. Card T, Logan RF, Rodrigues LC, Wheeler JG (2004) Antibiotic use and the development
of Crohn's disease. Gut 53: 246-250.
75. Margolis DJ, Fanelli M, Hoffstad O, Lewis JD (2010) Potential association; between the
oral tetracycline class of antimicrobials used to treat acne; and inflammatory bowel disease.
Am J Gastroenterol 105: 2610-2616.
76. Shaw SY, Blanchard JF, Bernstein CN (2011) Association between the use of antibiotics
and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol 106: 2133-
2142.
77. Lee TW, Russell L, Deng M, Gibson PR (2013) Association of doxycycline use with the
development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in
Australians deployed abroad. Intern Med J 43: 919-926.
78. Hildebrand, Hans, Malmborg, Petter, Askling, Johan, Ekbom, Anders, Montgomery,
Scott M. (2008), Early-life exposures associated with antibiotic use and risk of subsequent
Crohn's disease, Scandinavian Journal of Gastroenterology, vol. 43, no. 8, pp. 961-966.
79. Reddy, Deepa, Siegel, Corey A, Sands, Bruce E, Kane, Sunanda, (2006), Possible
association between isotretinoin and inflammatory bowel disease, American Journal of
80. Crockett, Seth D, Porter, Carol Q, Martin, Christopher F, Sandler, Robert S,
Kappelman,Michael D., (2010), Isotretinoin use and the risk of inflammatory bowel disease:
A case-control study, American Journal of Gastroenterology, vol. 105, no. 9, pp. 1986-1993.
81. Bernstein, Charles N, Nugent, Zoann, Longobardi, Teresa, Blanchard,James F. (2009),
Isotretinoin is not associated with inflammatory bowel disease: A population-based case-
control study, American Journal of Gastroenterology, vol. 104, no. 11, pp. 2774-2778.
82. Swidsinski, Alexander, Dietel, Manfred, Lochs, Herbert, Ladhoff, Axel, Pernthaler,
Annelie, Swidsinski, Sonja, Loening, Baucke, Vera, Ortner, Marianne, Weber, Jutta,
Hoffmann, Uwe,Schreiber, Stefan (2002), Mucosal flora in inflammatory bowel disease,
83. Sartor, R.B. (2006), Mechanisms of disease: Pathogenesis of Crohn's disease and
ulcerative colitis, Nature Clinical Practice Gastroenterology and Hepatology, vol. 3, no. 7, pp.
390-407.
84. Kim, SC, Tonkonogy, SL, Albright, CA,Sartor, RB. (2005). Different host genetic
backgrounds determine disease phenotypes induced by selective bacterial colonization.
Gastroenterology, 128(4), A512-A512.
85. Bibiloni, R., Simon, M.A., Albright, C., Sartor, B. and Tannock, G.W. (2005), Analysis
of the large bowel microbiota of colitic mice using PCR/DGGE. Letters in Applied
Microbiology, 41: 45–51.
86. Balish, E., & Warner, T. (2002). Enterococcus faecalis induces inflammatory bowel
disease in interleukin-10 knockout mice. The American Journal of Pathology, 160(6), 2253.
87. Holt, LC, Mann, B, Rocha, E,Sartor, RB. (2005). Heat shock protein (HSP) 60 from
bacteroides vulgatus stimulates proinflammatory cytokine production by rat splenocytes.
88. Bibiloni, Rodrigo, Fedorak, Richard N, Tannock, Gerald W, Madsen, Karen L,
Gionchetti, Paolo, Campieri, Massimo, De Simone, Claudio, Sartor,R.Balfour. (2005).
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.
89. Kuisma, J., Mentula, S., Jarvinen, H., Kahri, A., Saxelin, M. and Farkkila, M. (2003),
Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora.
Alimentary Pharmacology & Therapeutics, 17: 509–515.
90. Gionchetti, P, Rizzello, F, Venturi, A, Brigidi, P, Matteuzzi, D, Bazzocchi, G, Poggioli,
G, Miglioli, M,Campieri, M. (2000). Oral bacteriotherapy as maintenance treatment in
patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology,
119(2), 305-309.
91. Korzenik, J. R. (2005). Past and current theories of etiology of IBD: Toothpaste, worms,
and refrigerators. Journal of Clinical Gastroenterology, 39(4), S59-S65.
92. Hunter MM, Mckay DM. Helminths as therapeutic agents for inflammatory bowel
disease, (2004), Aliment Pharmacol Ther;19:167-77.
93. Summers, Robert W, Elliott, David E, Urban Jr, Joseph F, Thompson, Robin A,
Weinstock,Joel V. (2005). Trichuris suis therapy for active ulcerative colitis: A randomized
controlled trial. Gastroenterology, 128(4), 825-832.
94. Garcia Rodriguez LA, Ruigomez A, Panes J., (2006), Acute gastroenteritis is followed by
an increased risk of inflammatory bowel disease. Gastroenterology 130:1588-94.
95. Gradel, Kim O, Nielsen, Hans L, Schønheyder, Henrik C, Ejlertsen, Tove, Kristensen,
Brian,Nielsen, Henrik. (2009). Increased short- and long-term risk of inflammatory bowel
disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology, 137(2), 495-
501.
96. Luther, Jay, Dave, Maneesh, Higgins, Peter D. R, Kao,John Y. (2010). Association
between helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and
systematic review of the literature. Inflammatory Bowel Diseases, 16(6), 1077-1084.
97. Thomson, J. M., Hansen, R., Berry, S. H., Hope, M. E., Murray, G. I., Mukhopadhya, I.,
Hold, G. L. (2011). Enterohepatic Helicobacter in ulcerative colitis: Potential pathogenic
entities? PLoS One, 6(2).
98. Bohr, Ulrich R. M, Glasbrenner, Bernhard, Primus, Anett, Zagoura, Alexandra, Wex,
Thomas,Malfertheiner, Peter. (2004). Identification of enterohepatic helicobacter species in
patients suffering from inflammatory bowel disease. Journal of Clinical Microbiology, 42(6),
2766-2768.
99. Zhang L, Day A, McKenzie G, Mitchell H (2006) Nongastric helicobacter species
detected in the intestinal tract of children. J Clin Microbiol 44(6): 2276–2279;
100. Laharie D, Asencio C, Asselineau J, Bulois P, Bourreille A, et al. (2009) Association
between entero-hepatic Helicobacter species and Crohn's disease: A prospective cross-
sectional study. Aliment Pharmacol Ther 30(3): 283–293).
101. Koutroubakis, I, Manousos, O.N, Meuwissen, S.G.M,Pena, A.S. (1996). Environmental
risk factors in inflammatory bowel disease. Hepato-Gastroenterology, 43(8), 381-393.
102. Ouellette, Andre J, Bevins,Charles L. (2001). Measles virus and crohn's disease: A
critical appraisal of the current literature. Inflammatory Bowel Diseases, 7(1), 51-57.
103. Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA (2002) Role of appendicitis and
appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis
8:277–286.
104. Russel, M.G, Dorant, E, Brummer, R.-J.M, Van De Kruus, M.A, Muris, J.W, Bergers,
J.M, Goedhard, J,Stockbrugger, R.W. (1997). Appendectomy and the risk of developing
ulcerative colitis or Crohn's disease: Results of a large case-control study. Gastroenterology,
113(2), 377-382.
105. Radford-Smith GL, Edwards JE, Purdie DM, (2002), Protective role of appendicectomy
on onset and severity of ulcerative colitis and Crohn’s disease. Gut 51:808–813.
106. Roland E. Andersson, Gunnar Olaison, Curt Tysk, Anders Ekbom, (2001), N Engl J
Med; 344:808-814.
107. Bolin TD, Wong S, Crouch R, Engelman JL, Riordan SM, (2009), Appendicectomy as a
therapy for ulcerative proctitis . Am J Gastroenterol 104 2476-2482.
108. López-Serrano, Pilar, Pérez-Calle, José L, Pérez-Fernández, Maria Teresa, Fernández-
Font, Juan Manuel, Boixeda De Miguel, Daniel, Fernández-Rodríguez,Conrado M. (2010).
Environmental risk factors in inflammatory bowel diseases. investigating the hygiene
hypothesis: A spanish casecontrol study. Scandinavian Journal of Gastroenterology, 45(12),
1464-1471.
109. Klement, Eyal, Lysy, Joseph, Hoshen, Moshe, Avitan, Merav, Goldin, Eran,Israeli,
Eran. (2008). Childhood hygiene is associated with the risk for inflammatory bowel disease:
A population-based study. American Journal of Gastroenterology, 103(7), 1775-1782.
110. Anja Boneberger, Eduardo Hebel Weiss, Mario Calvo, Lilibeth Torres, Johanna
Wagner, Michael Kabesch, Katja Radon, (2011), Environmental factors in infancy and
ulcerative colitis in the Central South of Chile: A case–control study, Journal of Crohn's and
Colitis Volume 5, Issue 5, 392–396.
111. Benchimol, Eric I, Fortinsky, Kyle J, Gozdyra, Peter, Van Den Heuvel, Meta, Van
Limbergen, Johan, Griffiths,Anne M. (2011). Epidemiology of pediatric inflammatory bowel
disease: A systematic review of international trends. Inflammatory Bowel Diseases, 17(1),
423-439.
112. Khor, Bernard; Gardet, Agnès; Xavier, Ramnik J, (2011), Genetics and pathogenesis of
inflammatory bowel disease, Nature, ISSN 0028-0836, Volume 474, Issue 7351, pp. 307 –
317.
113. Tysk, C, Lindberg, E, Jarnerot, G,Floderus-Myrhed, B. (1988). Ulcerative colitis and
crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of
heritability and the influence of smoking. Gut, 29(7), 990-996.
114. Anderson CA, Boucher G, Lees CW et al, (2011), Meta-analysis identifies 29 additional
ulcerative colitis risk loci, increasing the number of confirmed associations to 47, Nat Genet
43:246–252.
115. UK IBD Genetics Consortium, Barrett JC, Lee JC et al (2009) Genome-wide association
study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A
region. Nat Genet 41:1330–1334.
116. McGovern DP, Gardet A, Torkvist L et al, (2010), Genome-wide association identifies
multiple ulcerative colitis susceptibility loci, Nat Genet 42:332–337.
117. Giallourakis, Cosmas, Stoll, Monika, Miller, Katie, Hampe, Jochen, Lander, Eric S,
Daly, Mark J, Schreiber, Stefan, Rioux,John D. (2003). IBD5 is a general risk factor for
inflammatory bowel disease: Replication of association with crohn disease and identification
of a novel association with ulcerative colitis. American Journal of Human Genetics, 73(1),
205-211.
118. Brant, Steven R, Wang, Ming-Hsi, Rawsthorne, Patricia, Sargent, Michael, Datta, Lisa
Wu, Nouvet, Franklin, Shugart, Yin Yao, Bernstein,Charles N. (2007). A population-based
case-control study of CARD15 and other risk factors in crohn's disease and ulcerative colitis.
119. Abreu, M. T. (2010). Toll-like receptor signalling in the intestinal epithelium: How
bacterial recognition shapes intestinal function. Nature Reviews: Immunology, 10(3), 215.
120. Hugot J-P, Chamaiilard M, Zouali H, (2001), Association of NOD2 leucine-rich repeat
variants with susceptibility to Crohn's disease. Nature;411:599-603.
121. Ogura Y, Bonen DK, Inohara N, et al, (2001), A frameshift mutation in NOD2
associated with susceptibility to Crohn's disease. Nature;411:603-606.
122. Hampe J, Franke A, Rosenstiel P, et al., (2007), A genome-wide association scan of
nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat
Genet;39:207-211.
123. Parkes M, Barrett JC, Prescott NJ, et al., (2007), Sequence variants in the autophagy
gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility.
Nat Genet;39:830-832.
124. Takahashi F, Das KM., (1985), Isolation and characterization of a colonic autoantigen
specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative
colitis. J Clin Invest;76:311-318.
125. Kaser A, Zeissing S, Blumberg RS., (2010), Inflammatory bowel disease. Annu Rev
Immunol;28:573-621.
126. Fuss, I. J., Heller, F., Boirivant, M., Leon, F., & al, e. (2004). Nonclassical CD1d-
restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative
colitis. Journal of Clinical Investigation, 113(10), 1490-7.
127. Heller, F, Fromm, M, Zeitz, M, Fuss, I, Strober, W, Schulzke, JD, Florian, P, Bojarski,
C, Richter, J, Christ, M, Hillenbrand, B, Mankertz, J, Gitter, AH,Burgel, N. (2005).
Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight
junctions, apoptosis, and cell restitution. Gastroenterology, 129(2), 550-564.
128. Fuss, IJ, Boirivant, M, Lacy, B,Strober, W. (2002). The interrelated roles of TGF-beta
and IL-10 in the regulation of experimental colitis. Journal Of Immunology, 168(2), 900-908.
129. Hanauer, S. B. (2006). Inflammatory bowel disease: Epidemiology, pathogenesis, and
therapeutic opportunities. Inflammatory Bowel Diseases, 12(1), S3-S9.
130. Panwala, Chetan M, Jones, Jon C, Viney,Joanne L. (1998). A novel model of
inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a,
spontaneously develop colitis. Journal of Immunology, 161(10), 5733-5744.
131. Hermiston, M. L., & Gordon, J. I. (1995). Inflammatory bowel disease and adenomas in
mice expressing a dominant negative n-cadherin. Science, 270(5239), 1203.
132. Stadnyk, A. W. (2002). Intestinal epithelial cells as a source of inflammatory cytokines
and chemokines. Canadian Journal of Gastroenterology, 16(4), 241-246.
133. Gibson P, Rosella O, Nov R, Young G., (1995) Colonic epithelium is diffusely abnormal
in ulcerative colitis and colorectal cancer. Gut;36:857-863.
134. Dubuquoy L, Jansson EA, Deeb S, et al., (2003), Impaired expression of peroxisome
proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology;124:1265-1276.
135. Tsukada, Yuriko, Nakamura, Tetsuo, Iimura, Mitsutoshi, Iizuka, Bun-Ei,Hayashi,
Naoaki. (2002). Cytokine profile in colonic mucosa of ulcerative colitis correlates with
disease activity and response to granulocytapheresis. American Journal of Gastroenterology,
97(11), 2820-2828.
136. Geng, X, Biancone, L, Hui Hui Dai, Lin, J.J.-C, Yoshizaki, N, Dasgupta, A, Pallone,
F,Das, K.M. (1998). Tropomyosin isoforms in intestinal mucosa: Production of
autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology, 114(5), 912-
922.
137. Bhagat S, Das KM. (1994), A shared and unique epitope in the human colon, eye, and
joint detected by a monoclonal antibody. Gastroenterology;107:103-108.
138. Jochen Maul, Martin Zeitz, (2011), Ulcerative colitis: immune function, tissue fibrosis
and current therapeutic considerations. Langenbeck's Archives of Surgery, Volume 397, Issue
1, pp 1-10.
139. Deusch, K, Mauthe, B, Reiter, C, Riethmuller, G,Classen, M. (1993). Cd4-Antibody
Treatment Of Inflammatory Bowel-Disease - One-Year Follow-Up. Gastroenterology,
104(4), A691-A691.
140. Okayasu, I., Yoshida, T., Mikami, T., Hana, K., Yokozawa, M., Araki, K., Mitsuhashi,
J., Kikuchi, M., Adachi, E. and Sada, M. (2009), Mucosal remodeling in long-standing
ulcerative colitis with colorectal neoplasia: Significant alterations of NCAM+ or α-SMA+
subepithelial myofibroblasts and interstitial cells. Pathology International, 59: 701–711.
141. Hall, LJ, Murphy, CT, Hurley, G, Quinlan, A, Shanahan, F, Nally, K,Melgar, S. (2013).
Natural killer cells protect against mucosal and systemic infection with the enteric pathogen
citrobacter rodentium. Infection and Immunity, 81(2), 460-469.
142. Mowat, Allan McI, Bain,Calum C. (2010). The curious case of the intestinal eosinophil.
Mucosal Immunology, 3(5), 420-421.
143. Lampinen, M, Winqvist, O, Carlson, M, Rönnblom, A, Amin, K, Kristjansson, G,
Rorsman, F, Sangfelt, P, Säfsten, B, Wagner, M,Wanders, A. (2005). Eosinophil granulocytes
are activated during the remission phase of ulcerative colitis. Gut, 54(12), 1714-1720.
144. Benedicte Y. De Winter, Rene M. van den Wijngaard, Wouter J. de Jonge, (2012),
Intestinal mast cells in gut inflammation and motility disturbances. Biochimica et Biophysica
Acta (BBA) - Molecular Basis of Disease Volume 1822, Issue 1, Pages 66–73.
145. Irina I. Stoyanova, Maya V. Gulubova, (2002), Mast cells and inflammatory mediators
in chronic ulcerative colitis, Acta Histochemica, Volume 104, Issue 2, Pages 185–192.
146. Nishida, Yoshiyuki, Murase, Kunihiko, Isomoto, Hajime, Furusu, Hisashi, Mizuta,
Yohei, Riddell, H. Robert,Kohno, Shigeru. (2002). Different distribution of mast cells and
macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel
disease. Hepato-Gastroenterology, 49(45), 678-682.
147. Hamilton, Matthew J, Lee, David M, Stevens, Richard L, Sinnamon, Mark J, Lyng,
Gregory D, Glickman, Jonathan N, Wang, Xueli, Xing, Wei, Krilise, Steven A, Blumberg,
Richard S,Adachi, Roberto. (2011). Essential role for mast cell tryptase in acute experimental
colitis. Proceedings of the National Academy of Sciences of the United States of America,
108(1), 290-295.
148. He, S. (2004). Key role of mast cells and their major secretory products in inflammatory
bowel disease. World Journal of Gastroenterology, 10(3), 309-318.
149. Raithel, M, Matek, M, Baenkler, H.W, Jorde, W,Hahn, E.G. (1995). Mucosal histamine
content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy.
International Archives of Allergy and Immunology, 108(2), 127-133.
150. Balázs, Martha, Illyés, György,Vadász, Gizella. (1989). Mast cells in ulcerative colitis -
quantitative and ultrastructural studies. Virchows Archiv B Cell Pathology Including
Molecular Pathology, 57(1), 353-360.
151. Kamada, N., Hisamatsu, T., Okamoto, S., Chinen, H., Kobayashi, T., Sato, T., Hibi, T.
(2008). Unique CD14^sup +^ intestinal macrophages contribute to the pathogenesis of crohn
disease via IL-23/IFN-gamma] axis. Journal of Clinical Investigation, 118(6), 2269-80.
152. Cosín-Roger, J., Ortiz-Masiá, D., Calatayud, S., Hernández, C., Álvarez, A., Hinojosa,
J., Barrachina, M. D. (2013). M2 macrophages activate WNT signaling pathway in epithelial
cells: Relevance in ulcerative colitis. PLoS One, 8(10).
153. Wang, Wei, Zhou, Yanhong, Li, Xiayu,Shen, Shourong. (2012). Effect of macrophages
on ulcerative colitis-associated carcinogenesis. Journal of Central South University (Medical
Sciences), 37(6), 637-641.
154. Rescigno, M., & Di Sabatino, A. (2009). Dendritic cells in intestinal homeostasis and
disease. Journal of Clinical Investigation, 119(9), 2441-50.
155. Steinbach, EC, Plevy, SE. (2014). The role of macrophages and dendritic cells in the
initiation of inflammation in IBD. Inflammatory Bowel Diseases, 20(1), 166-175.
156. Ikeda, Y, Akbar, F, Matsui, H,Onji, M. (2001). Characterization of antigen-presenting
dendritic cells in the peripheral blood and colonic mucosa of patients with ulcerative colitis.
European Journal of Gastroenterology and Hepatology, 13(7), 841-850.
157. Rieder F, Fiocchi C (2009) Intestinal fibrosis in IBD - a dynamic, multifactorial process.
Nat Rev Gastroenterol Hepatol 6:228–235.
158. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y,
Andoh A (2010) Interleukin-33 expression is specifically enhanced in inflamed mucosa of
ulcerative colitis. J Gastroenterol 45:999–1007.
159. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G,
Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-
1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper
type 2-associated cytokines. Immunity 23:479–490.
160. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK, Bourne PA,
Pierce RH, Kastelein R, Pflanz S (2010) IL-33 induces IL-13-dependent cutaneous fibrosis. J
Immunol 184:1526–1535.
161. Powell, D.W, Mifflin, R.C, Valentich, J.D, Crowe, S.E, Saada, J.I,West, A.B. (1999).
Myofibroblasts. II. intestinal subepithelial myofibroblasts. American Journal of Physiology -
Cell Physiology, 277(2), C183-C201.
162. Allaire, JM, Roy, SA, Keatsner, KH, Boudreau, F,Perreault, N. (2011). Loss of BMP
signaling in subepithelial myofibroblasts leads to colonic dysplasia and impacts on ulcerative
colitis. International Journal of Molecular Medicine, 28, S17-S17.
163. Jobson, Timothy M, Billington, Charlotte K, Hall, Ian P. (1998). Regulation of
proliferation of human colonic subepithelial myofibroblasts by mediators important in
intestinal inflammation. Journal of Clinical Investigation, 101(12), 2650-2657.
164. Okayasu, I. (2012), Development of ulcerative colitis and its associated colorectal
neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence.
Pathology International, 62: 368–380.
165. Whiting, Christine V, Tarlton, John F, Bailey, Michael, Morgan, Clare L, Bland,Paul W.
(2003). Abnormal mucosal extracellular matrix deposition is associated with increased TGF-
β receptor-expressing mesenchymal cells in a mouse model of colitis. Journal of
Histochemistry and Cytochemistry, 51(9), 1177-1189.
166. Järveläinen, Hannu, Sainio, Annele, Koulu, Markku, Wight, Thomas N,Penttinen, Risto.
(2009). Extracellular matrix molecules: Potential targets in pharmacotherapy.
Pharmacological Reviews, 61(2), 198-223.
167. Whiting, Christine V, Tarlton, John F, Bailey, Michael, Morgan, Clare L, Bland,Paul W.
(2003). Abnormal mucosal extracellular matrix deposition is associated with increased TGF-
β receptor-expressing mesenchymal cells in a mouse model of colitis. Journal of
Histochemistry and Cytochemistry, 51(9), 1177-1189.
168. Lawrance, IC, Chakravarti, S. (2000). Distinctive expression patterns of extracellular
matrix (ECM) and ECM remodeling genes in ulcerative colitis (UC) and Crohn's disease
(CD). Gastroenterology, 118(4), A797-A797.
169. de la Motte CA, Hascall VC, Drazba J, Bandyopadhyay SK, and Strong SA (2003)
Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth
muscle cells treated with polyinosinic acid:polycytidylic acid: inter-alphatrypsin inhibitor is
crucial to structure and function. Am J Pathol 163 121-133.
170. Gábor Lakatos, Ferenc Sipos, 2, Pál Miheller, István Hritz, Mária Zsófia Varga, Márk
Juhász, Béla Molnár, Zsolt Tulassay and László Herszényi, (2012), The Behavior of Matrix
Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis.
Pathology & Oncology Research, Volume 18, Issue 1, pp 85-91.
171. H. Nagase, J. F. Woessner Jr., (1999), Matrix metalloproteinases, The Journal of
Biological Chemistry, vol. 274, no. 31, pp. 21491–21494.
172. C. M. Overall, C. López-Otín, (2002), Strategies for MMP inhibition in cancer:
innovations for the post-trial era, Nature Reviews Cancer, vol. 2, no. 9, pp. 657–672.
173. Visse, Robert, Nagase, Hideaki. (2003). Matrix metalloproteinases and tissue inhibitors
of metalloproteinases: Structure, function, and biochemistry. Circulation Research, 92(8),
827-839.
174. Christopher M. Overall, (2002), Molecular determinants of metalloproteinase substrate
specificity, Molecular Biotechnology, Volume 22, Issue 1, pp 51-86.
175. Khokha, R., Murthy, A., & Weiss, A. (2013). Metalloproteinases and their natural
inhibitors in inflammation and immunity.Nature Reviews.Immunology, 13(9), 649-65.
176. Parks, W. C., Wilson, C. L., & López-Boado, Y.,S. (2004). Matrix metalloproteinases as
modulators of inflammation and innate immunity. Nature Reviews.Immunology, 4(8), 617-
29.
177. Keith Brewa, Hideaki Nagase, (2010), The tissue inhibitors of metalloproteinases
(TIMPs): An ancient family with structural and functional diversity, Biochimica et
Biophysica Acta (BBA) - Molecular Cell Research, Volume 1803, Issue 1, Pages 55–71.
178. Palosaari, H., Pennington, C. J., Larmas, M., Edwards, D. R., Tjäderhane, L. and Salo,
T. (2003), Expression profile of matrix metalloproteinases (MMPs) and tissue inhibitors of
MMPs in mature human odontoblasts and pulp tissue. European Journal of Oral Sciences,
111: 117–127.
179. Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell
behavior. Annual Review of Cell and Developmental Biology, 17, 463-516.
180. Medina, C., Santos-Martinez, M. J., Santana, A., Paz-Cabrera, M. C., Johnston, M. J.,
Mourelle, M., Salas, A. and Guarner, F. (2011), Transforming growth factor-beta type 1
receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental
intestinal fibrosis. J. Pathol., 224: 461–472.
181. McKaig, BC, Collins, H, Hawkey, CJ, Watson, S,Mahida, YR. (2000). Expression of
matrix metalloproteinases (MMPS) and tissue inhibitors of metalloproteinases (TIMPS) by
human intestinal myofibroblasts. Gastroenterology, 118(4), A551-A551.
182. Foegh, P, Pedersen, G, Saermark, T,Brynskov, J. (2000). mRNA expression of matrix
metalloproteinases (MMP) and their natural tissue inhibitors (TIMP) in patients with
inflammatory bowel disease (IBD). Gastroenterology, 118(4), A799-A799.
183. Rundhaug, J. E. (2005). Matrix metalloproteinases and angiogenesis. Journal of Cellular
and Molecular Medicine, 9(2), 267-85.
184. Wiercinska-Drapalo, Alicja, Jaroszewicz, Jerzy, Flisiak, Robert,Prokopowicz, Danuta.
(2003). Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as
biomarkers of ulcerative colitis activity. World Journal of Gastroenterology, 9(12), 2843-
2845.
185. B, v. L., Barthel, B., Coupland, S. E., E-O Riecken, & Rosewicz, S. (2000). Differential
expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients
with inflammatory bowel disese. Gut, 47(1), 63-73.
186. Rath, Timo, Roderfeld, Martin, Halwe, Jörg Michael, Tschuschner, Annette, Roeb,
Elke,Graf, Jürgen. (2010). Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative
colitis. Scandinavian Journal of Gastroenterology, 45(10), 1186-1196.
187. Rath, Timo, Roderfeld, Martin, Graf, Jürgen, Wagner, Sandra, Vehr, Ann-Kathrin,
Dietrich, Christoph, Geier, Andreas,Roeb, Elke. (2006). Enhanced expression of MMP-7 and
MMP-13 in inflammatory bowel disease: A precancerous potential? Inflammatory Bowel
Diseases, 12(11), 1025-1035.
188. Garg, Pallavi, Rojas, Mauricio, Ravi, Anupama, Bockbrader, Katrina, Epstein, Steven,
Vijay-Kumar, Matam, Gewirtz, Andrew T, Merlin, Didier, Sitaraman,Shanthi V. (2006).
Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: Contrasting
role of gelatinases in the pathogenesis of colitis. Journal of Immunology, 177(6), 4103-4112.
189. Koller, F. L., Dozier, E. A., Nam, K. T., Swee, M., Birkland, T. P., Parks, W. C., &
Fingleton, B. (2012). Lack of MMP10 exacerbates experimental colitis and promotes
development of inflammation-associated colonic dysplasia. Laboratory Investigation, 92(12),
1749-1759.
190. Bachmeier, B. E., Iancu, C. M., Jochum, M., & Nerlich, A. G. (2005). Matrix
metalloproteinases in cancer: Comparison of known and novel aspects of their inhibition as a
therapeutic approach. Expert Review of Anticancer Therapy, 5(1), 149-63.
191. Gomperts, Brigitte N, Strieter,Robert M. (2006). Chemokine-directed metastasis.
Contributions to Microbiology, 13, 170-190.
192. Li, A. C. Y., & Thompson, R. P. H. (2003). Basement membrane components. Journal
of Clinical Pathology, 56(12), 885-7.
193. Koutroubakis, I. E., Petinaki, E., Dimoulios, P., Vardas, E., & al, (2003). Serum laminin
and collagen IV in inflammatory bowel disease. Journal of Clinical Pathology, 56(11), 817-
20.
194. Appleyard, CB, Hanson, LJ,Percy, WH. (1998). Temporal changes in inflammatory
mediator levels and colonic vascular architecture in an animal model of colitis.
195. Grisham, Matthew B, Kevil, Christopher G, Harris, Norman R, Granger,D.Neil. (2010).
The role of the vasculature in chronic intestinal inflammation. (pp. 157-169).
196. Furukawa, H., Inoue, F., Miyake, N., Moriyasu, T., Moriti, H. and Saiga, T. (2004),
Three-dimensional reconstruction of the mucosa from sequential sections of biopsy
specimens of patients with ulcerative colitis: Relationship between crypt structure and
vascular architecture. Digestive Endoscopy, 16: 107–112.
197. Geboes, K. and Collins, S. (1998), Structural abnormalities of the nervous system in
Crohn's disease and ulcerative colitis. Neurogastroenterology & Motility, 10: 189–202.
198. Coates, Matthew D, Mawe, Gary M, Moses, Peter L, Mahoney, Christine R, Linden,
David R, Sampson, Joanna E, Chen, Jason, Blaszyk, Hagen, Crowell, Michael D, Sharkey,
Keith A, Gershon,Michael D. (2004). Molecular defects in mucosal serotonin content and
decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.
199. Duff, Sarah E, Li, Chenggang, Garland, John M,Kumar, Shant. (2003). CD105 is
important for angiogenesis: Evidence and potential applications. FASEB Journal, 17(9), 984-
992.
200. Nassiri, Farshad, Cusimano, Michael D, Scheithauer, Bernd W, Rotondo, Fabio, Fazio,
Alessandra, Yousef, George M, Syro, Luis V, Kovacs, Kalman, Lloyd,Ricardo V. (2011).
Endoglin (CD105): A review of its role in angiogenesis and tumor diagnosis, progression and
therapy. Anticancer Research, 31(6), 2283-2290.
201. Middleton, J., Americh, L., Gayon, R., Julien, D., Mansat, M., Mansat, P., Anract, P.,
Cantagrel, A., Cattan, P., Reimund, J.-M., Aguilar, L., Amalric, F. and Girard, J.-P. (2005), A
comparative study of endothelial cell markers expressed in chronically inflamed human
tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31,
CD34, CD105 and CD146. J. Pathol., 206: 260–268.
202. Koutroubakis, I. E., Tsiolakidou, G., Karmiris, K. and Kouroumalis, E. A. (2006), Role
of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis, 12: 515–523.
203. Kanazawa, S, Tsunoda, T, Onuma, E, Majima, T, Kagiyama, M,Kikuchi, K. (2001).
VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: A novel
mechanism of chronic intestinal inflammation. American Journal Of Gastroenterology,
96(3), 822-828.
204. Griga, Thomas, Voigt, Edgar, Gretzer, Britta, Brasch, Frank,May, Burkard. (1999).
Increased production of vascular endothelial growth factor by intestinal mucosa of patients
with inflammatory bowel disease. Hepato-Gastroenterology, 46(26), 920-923.
205. Tolstanova, Ganna, Khomenko, Tetyana, Deng, Xiaoming, Chen, Longchuan,
Tamawski, Andrzej, Ahluwalia, Amrita, Szabo, Sandor,Sandor, Zsuzsanna. (2009).
Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of
experimental ulcerative colitis in rats: Direct evidence for the pathogenic role of VEGF.
Journal of Pharmacology and Experimental Therapeutics, 328(3), 749-757.
206. Kohyama M, Sugahara D, Hosokawa H, Kubo M, Hozumi N., (2001), IL-4 mediated
development of TGF-β1-producing cells from naïve CD4+ T cells through a STAT6-
independent mechanism. Eur J Immunol; 31: 3659–66.
207. Odes, S., Vardi, H., Friger, M., Esser, D., Wolters, F., Moum, B., Waters, H., Elkjaer,
M., Bernklev, T., Tsianos, E., O’Morain, C., Stockbrügger, R., Munkholm, P. and Langholz,
E. (2010), Clinical and economic outcomes in a population-based European cohort of 948
ulcerative colitis and Crohn’s disease patients by Markov analysis. Alimentary Pharmacology
& Therapeutics, 31: 735–744.
208. Kornbluth, Asher, Sachar, David B,Amer Coll Gastroenterology. (2010). Ulcerative
colitis practice guidelines in adults: American college of gastroenterology, practice
parameters committee. American Journal of Gastroenterology, 105(3), 501-523.
209. S. Ardizzone, P.S. Puttini, A. Cassinotti, G. Bianchi-Porro, (2008), Extraintestinal
manifestations of inflammatory bowel disease, Dig Liver Dis, 40 (Suppl. 2) pp. S253–S259.
210. Su CG, Judge TA, Lichtenstein GR., (2002), Extraintestinal manifestations of
inflammatory bowel disease. Gastroenterol Clin North Am;31:307–27.
211. Annese V, Daperno M, Rutter MD, et al., (2013), European evidence based consensus
for endoscopy in inflammatory bowel disease. J Crohn's Colitis;7:982–1018.
212. Magro F, Langner C, Driessen A, et al., (2013), European consensus on the
histopathology of inflammatory bowel disease. J Crohn's Colitis;7:827–51.
213. Matsumoto T, Nakamura S, Shimizu M, et al., (2002), Significance of appendiceal
involvement in patients with ulcerative colitis. Gastrointest Endosc.;55:180-185.
214. Valdez R, Appelman H, Bronner MP, et al., (2000), Diffuse duodenitis associated with
ulcerative colitis. Am J Surg Pathol; 24:1407–1413.
215. Fefferman DS, Farrell RJ., (2005) Endoscopy in inflammatory bowel disease:
indications, surveillance, and use in clinical practice. Clin Gastroentero Hepatol.;3:11-24.
216. Samuel, Sunil, de Groen, Piet C, Harmsen, William S, Zinsmeister, Alan R, Sandborn,
William J, Bruining, David H, Loftus, Edward V, Thia, Kelvin T, Schroeder, Kenneth W,
Tremaine, William J, Faubion, William A, Kane, Sunanda V, Pardi,Darrell S. (2013).
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with
disease activity measures. Clinical Gastroenterology and Hepatology, 11(1), 49-U178.
217. J.A. Leighton, B. Shen, T.H. Baron, et al., (2006), Standards of Practice Committee
American Society for Gastrointestinal Endoscopy. ASGE guideline: endoscopy in the
diagnosis and treatment of inflammatory bowel disease, Gastrointest Endosc, 63, pp. 558–
565.
218. Kornbluth AA, Kamm MA, Lichtenstein GR, et al., (2007), Symptomatic resolution is
an inadequate predictor of complete colonic mucosal healing in mild-to-moderate ulcerative
colitis. Gastroenterology;132:A-506.
219. Itzkowitz SH, Present DH., (2005), Consensus Conference: Colorectal Cancer Screening
and Surveillance in Inflammatory Bowel Disease. Inflamm Bowel Dis.;11:314-321.
220. Rutter, Matt, Bernstein, C, Matsumoto, T, Kiesslich, R,Neurath, M. (2004). Endoscopic
appearance of dysplasia in ulcerative colitis and the role of staining. Endoscopy, 36(12),
1109-1114.
221. Kiesslich, Ralf, Neurath, Markus F, Fritsch, Johannes, Holtmann, Martin, Koehler,
Heinz H, Stolte, Manfred, Kanzler, Stephan, Nafe, Bernhard, Jung, Michael, Galle,Peter R.
(2003). Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia
and colon cancer in ulcerative colitis. Gastroenterology, 124(4), 880-888.
222. M. Naganuma, H. Ichikawa, N. Inoue et al., (2010), Novel endoscopic activity index is
useful for choosing treatment in severe active ulcerative colitis patients,” Journal of
Gastroenterology, vol. 45, no. 9, pp. 936–943.
223. Hurlstone, DP, Sanders, DS, Lobo, AJ, McAlindon, ME,Cross, SS. (2005). Indigo
carmine-assisted high-magnification chromoscopic colonoscopy for the detection and
characterisation of intraepithelial neoplasia in ulcerative colitis: A prospective evaluation.
Endoscopy, 37(12), 1186-1192.
224. Travis, Simon P.L, Lichtenstein, Gary R, Marteau, Phillippe R, Reinisch, Walter, Sands,
Bruce E, Yacyshyn, Bruce R, Bernhardt, Christian A, Mary, Jean-Yves, Sandborn, William J,
Schnell, Dan, Krzeski, Piotr, Abreu, Maria T, Altman, Douglas G, Colombel, Jean-Frédéric,
Feagan, Brian G, Hanauer, Stephen B,Lémann, Marc. (2012). Developing an instrument to
assess the endoscopic severity of ulcerative colitis: The ulcerative colitis endoscopic index of
severity (UCEIS). Gut, 61(4), 535-542.
225. Bewtra, Meenakshi, Brensinger, Colleen M, Tomov, Vesselin T, Hoang, Tram B,
Sokach, Carly E, Siegel, Corey A, Lewis, James D. (2014). An optimized patient-reported
ulcerative colitis disease activity measure derived from the Mayo score and the simple
clinical colitis activity index. Inflammatory Bowel Diseases, 20(6), 1070-1078.
226. Vermeire, S, Van Assche, G, Rutgeerts, P. (2006). Laboratory markers in IBD: Useful,
magic, or unnecessary toys? Gut, 55(3), 426-431.
227. Bossuyt, X. (2006). Serologic markers in inflammatory bowel disease. Clinical
Chemistry, 52(2), 171-81.
228. Vermeire, Séverine, Van Assche, Gert,Rutgeerts, Paul. (2004). C-reactive protein as a
marker for inflammatory bowel disease. Inflammatory Bowel Diseases, 10(5), 661-665.
229. Lindgren, Stefan C, Flood, Lars M, Kilander, Anders F, Löfberg, Robert, Persson, Tore
B, Sjödahl,Rune I. (1998). Early predictors of glucocorticosteroid treatment failure in severe
and moderately severe attacks of ulcerative colitis. European Journal of Gastroenterology and
Hepatology, 10(10), 831-835.
230. Umehara, Yasushi, Kudo, Masatoshi, Nakaoka, Ryosuke, Kawasaki, Toshihiko,Shiomi,
Mikio. (2006). Serum proinflammatory cytokines and adhesion molecules in ulcerative
colitis. Hepato-Gastroenterology, 53(72), 879-882.
231. Hanai, H, Matsushita, I, Iwaoka, Y, Saniabadi, A, Watanabe, F, Yamada, M, Sato, Y,
Takeuchi, K, Iida, T, Tozawa, K, Tanaka, T,Maruyama, Y. (2004). Correlation of serum
soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative
colitis. American Journal Of Gastroenterology, 99(8), 1532-1538.
232. Komatsu, M, Watanabe, N, Kobayashi, D, Saito, K, Furuya, D, Yagihashi, A, Araake,
H, Tsuji, N, Sakamaki, S,Niitsu, Y. (2001). Tumor necrosis factor-alpha in serum of patients
with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clinical
Chemistry, 47(7), 1297-1301.
233. Sandborn WJ, Loftus EV Jr, Homburger HA, et al, (2001), Evaluation of serological
disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's
disease. Inflamm Bowel Dis Aug;7(3):192-201.
234. Langhorst, Jost, Elsenbruch, Sigrid, Koelzer, Julia, Rueffer, Andreas, Michalsen,
Andreas, Dobos,Gustav J. (2008). Noninvasive markers in the assessment of intestinal
inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin,
and PMN-elastase, CRP, and clinical indices. American Journal of Gastroenterology, 103(1),
162-169.
235. Costa, F, Mumolo, M.G, Ceccarelli, L, Bellini, M, Romano, M.R, Sterpi, C, Ricchiuti,
A, Marchi, S,Bottai, M. (2005). Calprotectin is a stronger predictive marker of relapse in
ulcerative colitis than in crohn's disease. Gut, 54(3), 364-368.
236. Abraham, Bincy P,Kane, Sunanda. (2012). Fecal markers: Calprotectin and lactoferrin.
Gastroenterology Clinics of North America, 41(2), 483-495.
237. F. Maccioni, M. C. Colaiacomo, S. Parlanti, (2005), Ulcerative colitis: value of MR
imaging, Abdominal Imaging, Volume 30, Issue 5, pp 584-592.
238. Thoeni, Ruedi F, Cello,John P. (2006). CT imaging of colitis. Radiology, 240(3), 623-
638.
239. Appleman, H. D. (2008). What are the critical histologic features in the diagnosis of
ulcerative colitis? Inflammatory Bowel Diseases, 14, S164-S165.
240. Tanaka, M., Saito, H., Kusumi, T., Fukuda, S., Shimoyama, T., Sasaki, Y., Suto, K.,
Munakata, A. and Kudo, H. (2001), Spatial distribution and histogenesis of colorectal Paneth
cell metaplasia in idiopathic inflammatory bowel disease. Journal of Gastroenterology and
Hepatology, 16: 1353–1359.
241. Johansson ME, Hansson GC (2013) Mucus and the goblet cell. Dig Dis 31: 305–309.
242. Gersemann M, Becker S, Kübler I, Koslowski M, Wang G, et al. (2009) Differences in
goblet cell differentiation between Crohn’s disease and ulcerative colitis. Differentiation 77:
84–94.
243. Geboes, K. (2001). Crohn's disease, ulcerative colitis or indeterminate colitis - how
important is it to differentiate? Acta Gastro-Enterologica Belgica, 64(2), 197-200.
244. Okamoto, Ryuichi,Watanabe, Mamoru. (2012). Mechanism of mucosal regeneration in
inflammatory bowel disease. Nihon Rinsho.Japanese Journal of Clinical Medicine, 70, 116-
121.
245. Geboes K, Riddell R, Öst Ä, et al., (2000), A reproducible grading scale for histological
assessment of inflammation in ulcerative colitis. Gut; 47:404–409.
246. Tze S. Khor, Hiroshi Fujita, Koji Nagata, Michio Shimizu, Gregory Y. Lauwers, (2012),
Biopsy interpretation of colonic biopsies when inflammatory bowel disease is excluded,
Journal of Gastroenterology, Volume 47, Issue 3, pp 226-248.
247. Carpenter, Herschel A, Talley,Nicholas J. (2000). The importance of clinicopathological
correlation in the diagnosis of inflammatory conditions of the colon: Histological patterns
with clinical implications. American Journal of Gastroenterology, 95(4), 878-896.
248. Torres, Joana, Billioud, Vincent, Sachar, David B, Peyrin-Biroulet, Laurent,Colombel,
Jean-Fred́ éric. (2012). Ulcerative colitis as a progressive disease: The forgotten evidence.
Inflammatory Bowel Diseases, 18(7), 1356-1363.
249. Winther, KV, Jess, T, Langholz, E, Munkholm, P,Binder, V. (2003). Survival and cause-
specific mortality in ulcerative colitis: Follow-up of a population-based cohort in copenhagen
county. Gastroenterology, 125(6), 1576-1582.
250. Solberg IC, Lygren I, Jahnsen J, et al., (2009), Clinical course during the first 10 years
of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand
J Gastroenterol.;44:431–440.
251. Meucci G, Vecchi M, Astegiano M, et al., (2000), The natural history of ulcerative
proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie
Intestinali (GSMII). Am J Gastroenterol.;95:469–473.
252. Chatzicostas C, Roussomoustakaki M, Potamianos S, et al., (2006), Factors associated
with disease evolution in Greek patients with inflammatory bowel disease. BMC
Gastroenterol.;6:21.
253. Mathy, Christian, Schneider, Ken, Chen, Yunn-Yi, Varma, Madhulika, Terdiman,
Jonathan P,Mahadevan, Uma. (2003). Gross versus microscopic pancolitis and the occurrence
of neoplasia in ulcerative colitis. Inflammatory Bowel Diseases, 9(6), 351-355.
254. Subramanian, V., Banerjee, A., Beharry, N., Farthing, M. J. G. And Pollok, R. C. G.
(2007), Determining the proximal extent of ulcerative colitis: white cell scan correlates well
with histological assessment. Alimentary Pharmacology & Therapeutics, 25: 441–446.
255. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF:, (2010), Clinical
implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol.;
7: 15-29.
256. Lichtenstein GR, Rutgeerts P:, (2010), Importance of mucosal healing in ulcerative
colitis. Inflamm Bowel Dis.; 16: 38-46.
257. Frøslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN Group, (2007), Mucosal healing in
inflammatory bowel disease: results from a Norwegian population- based cohort.
Gastroenterology; 133:412-422.
258. Geboes K, Dalle I., (2002), Influence of treatment on morphological features of mucosal
inflammation. Gut.;50 Suppl 3:III37-III42.
259. Bitton, Alain, Deb Edwardes, Michael D, Stevens, Anthony C, Peppercorn, Mark A,
Antonioli, Donald A, Niles, John L, Shah, Samir, Bousvaros, Athos, Ransil, Bernard, Wild,
Gary,Cohen, Albert. (2001). Clinical, biological, and histologic parameters as predictors of
relapse in ulcerative colitis. Gastroenterology, 120(1), 13-20.
260. Vincenzo Villanacci, Elisabetta Antonelli, Gianpaolo Reboldi, Marianna Salemme,
Giovanni Casella, Gabrio Bassotti, (2014), Endoscopic biopsy samples of naïve “colitides”
patients: Role of basal plasmacytosis, Journal of Crohn's and Colitis, Volume 8, Issue 11,
Pages 1438–1443.
261. Bessissow, Talat, De Hertogh, Gert, Lemmens, Bart, Ferrante, Marc, Bisschops, Raf,
Van Steen, Kristel, Geboes, Karel, Van Assche, Gert, Vermeire, Séverine, Rutgeerts, Paul.
(2012). Prognostic value of serologic and histologic markers on clinical relapse in ulcerative
colitis patients with mucosal healing. American Journal of Gastroenterology, 107(11), 1684-
1692.
262. Gupta, Roopali Bansal, Harpaz, Noam, Itzkowitz, Steven, Hossain, Sabera, Matula,
Sierra, Kornbluth, Asher, Bodian, Carol,Ullman, Thomas. (2007). {A figure is
presented}histologic inflammation is a risk factor for progression to colorectal neoplasia in
ulcerative colitis: A cohort study. Gastroenterology, 133(4), 1099-1105.
263. Langholz, E, Munkholm, P, Davidsen, M, Nielsen, O.H,Binder, V. (1996). Changes in
extent of ulcerative colitis: A study on the course and prognostic factors. Scandinavian
Journal of Gastroenterology, 31(3), 260-266.
264. Colombel, Jean Frédéric, Feagan, Brian G, Hanauer, Stephen B, Lichtenstein, Gary R,
Present, Daniel, Sands, Bruce E, Sandborn, William J, Rutgeerts, Paul, Reinisch, Walter,
Esser, Dirk, Wang, Yanxin, Lang, Yinghua, Marano, Colleen W, Strauss, Richard,
Oddens,Björn J. 2011, "Early mucosal healing with infliximab is associated with improved
long-term clinical outcomes in ulcerative colitis", Gastroenterology, vol. 141, no. 4, pp. 1194-
1201.
265. Ardizzone, Sandro, Maconi, Giovanni, Porro, Gabriele Bianchi, Cassinotti, Andrea,
Duca, Piergiorgio, Mazzali, Cristina, Penati, Chiara, Manes, Gianpiero, Marmo, Riccardo,
Massari, Alessandro,Molteni, Paola 2011, Mucosal Healing Predicts Late Outcomes After the
First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis, Clinical
Gastroenterology and Hepatology, vol. 9, no. 6, pp. 483-U117.
266. Lim, C. H., Dixon, M. F., Vail, A., Forman, D., & al, e. (2003). Ten year follow up of
ulcerative colitis patients with and without low grade dysplasia. Gut, 52(8), 1127-32.
267. Heuschen, Udo A, Hinz, Ulf, Allemeyer, Erik H, Stern, Josef, Lucas, Matthias,
Autschbach, Frank, Herfarth, Christian,Heuschen, Gundi 2001, Backwash ileitis is strongly
associated with colorectal carcinoma in ulcerative colitis, Gastroenterology, vol. 120, no. 4,
pp. 841-847.
268. Haskell, Henry, Andrews Jr, Charles W, Ready, Sarathchandra I, Dendrinos, Klea,
Farraye, Francis A, Stucchi, Arthur F, Becker, James M, Odze,Robert D. 2005, Pathologic
features and clinical significance of "backwash" ileitis in ulcerative colitis, American Journal
of Surgical Pathology, vol. 29, no. 11, pp. 1472-1481.
269. Walsh, S.V, Loda, M, Torres, C.M, Antonioli, D, Odze,Robert D. (1999). p53 and β
catenin expression in chronic ulcerative colitis-associated polypoid dysplasia and sporadic
adenomas: An immunohistochemical study. American Journal of Surgical Pathology, 23(8),
963-969.
270. Azad, S., Sood, N., & Sood, A. (2011). Biological and histological parameters as
predictors of relapse in ulcerative colitis: A prospective study. Saudi Journal of
271. Feakins, R. (2013). Inflammatory bowel disease biopsies: Updated british society of
gastroenterology reporting guidelines. Journal of Clinical Pathology, 66(12), 1005-1026.
272. Hlavaty, Tibor, Huorka, Martin, Koller, Tomas, Zita, Peter, Kresanova, Ema, Rychly,
Boris,Toth, Jozef. (2011). Colorectal cancer screening in patients with ulcerative and crohn's
colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. European
Journal of Gastroenterology and Hepatology, 23(8).
273. Geboes, K. (2001), Pathology of inflammatory bowel diseases (IBD): variability with
time and treatment. Colorectal Disease, 3: 2–12.
274. Stack, Long and Hawkey (1998), Short- and long-term outcome of patients treated with
cyclosporin for severe acute ulcerative colitis. Alimentary Pharmacology & Therapeutics, 12:
973–978.
275. Chey, W. Y. (2001). Infliximab for patients with refractory ulcerative colitis.
Inflammatory Bowel Diseases, 7(1), S30-S33.
276. Rutgeerts, Paul, Vermeire, Severine,Van Assche, Gert. (2007). Mucosal healing in
inflammatory bowel disease: Impossible ideal or therapeutic target? Gut, 56(4), 453-455.
277. Pera, A, Verme, G, Bellando, P, Caldera, D, Ponti, V, Astegiano, M, Barletti, C, David,
E, Arrigoni, A,Rocca, G. (1987). Colonoscopy in inflammatory bowel disease. diagnostic
accuracy and proposal of an endoscopic score. Gastroenterology, 92(1), 181-185.
278. Philpotts, Liane E, Heiken, Jay P, Westcott, Mark A, Gore,Richard M. (1994). Colitis:
Use of CT findings in differential diagnosis. Radiology, 190(2), 445-449.
279. Philpotts, Liane E, Heiken, Jay P, Westcott, Mark A, Gore,Richard M. (1994). Colitis:
Use of CT findings in differential diagnosis. Radiology, 190(2), 445-449.
280. Lisa A. Cerilli, Joel K. Greenson, (2012) The Differential Diagnosis of Colitis in
Endoscopic Biopsy Specimens: A Review Article. Archives of Pathology & Laboratory
Medicine: August 2012, Vol. 136, No. 8, pp. 854-864.
281. Mantzaris GJ. Endoscopic diagnosis of infectious colitis., (2007), Ann
Gastroenterol.;20:71–4.
282. Galiatsatos P, Shrier I, Lamoureux E, Szilagyi A., 2005, Meta-analysis of outcome of
cytomegalovirus colitis in immunocompetent hosts. Dig Dis Sci.;50:609–16.
283. Misra SP, Misra V, Dwivedi M, Gupta SC., (1999), Colonic tuberculosis: clinical
features, endoscopic appearance and management. J Gastroenterol Hepatol.;14:723–9.
284. Pulimood AB, Amarapurkar DN, Ghoshal U, Phillip M, Pai CG, Reddy DN, et al.,
(2011), Differentiation of Crohn’s disease from intestinal tuberculosis in India in 2010.
World J Gastroenterol.;17:433–43.
285. Yan, B.M,Shaffer, E.A. (2009). Primary eosinophilic disorders of the gastrointestinal
tract. Gut, 58(5), 721-732.
286. Klein, A., & Eliakim, R. (2010). Non steroidal anti-inflammatory drugs and
inflammatory bowel disease. Pharmaceuticals, 3(4), 1084-1092.
287. Habib, I., A. Mazulis, G. Roginsky, and ED Ehrenpreis. 2014. Nonsteroidal anti-
inflammatory drugs and inflammatory bowel disease: Pathophysiology and clinical
associations. Inflammatory bowel diseases 20, (12): 2493-2502..
288. Makapugay LM, Dean PJ., 1996, Diverticular-disease-associated chronic colitis. Am J
Surg Pathol; 20:94–102.
289. Paul Feuerstadt, Lawrence J. Brandt, (2010), Colon Ischemia: Recent Insights and
Advances, Current Gastroenterology Reports, Volume 12, Issue 5, pp 383-390.
290. Higgins, P. D. R., Davis, K. J. and Laine, L. (2004), The epidemiology of ischaemic
colitis. Alimentary Pharmacology & Therapeutics, 19: 729–738.
291. Liszka, Ł., Woszczyk, D. and Pająk, J. (2006), Histopathological diagnosis of
microscopic colitis. Journal of Gastroenterology and Hepatology, 21: 792–797.
292. Robert ME; Mohamed N, Marais M, Bezuidenhout J. Microscopic colitis as a missed
cause of chronic diarrhea. World J Gastroenterol 2011;17:1996–2002.
293. Lim, A. G., Langmead, F. L., Feakins, R. M., & Rampton, D. S. (1999). Diversion
colitis: A trigger for ulcerative colitis in the in-stream colon? Gut, 44(2), 279-82.
294. Mehta, S. J., Silver, A. R. and Lindsay, J. O. (2013), Review article: strategies for the
management of chronic unremitting ulcerative colitis. Alimentary Pharmacology &
Therapeutics, 38: 77–97.
295. Heikens, J. T., de Vries, J., de Jong, D. J., den Oudsten, B. L., Hopman, W.,
Groenewoud, J. M. M., van der Kolk, M. B., Gooszen, H. G. and van Laarhoven, C. J. H. M.
(2013), Evaluation of long-term function, complications, quality of life and health status after
restorative proctocolectomy with ileo neo rectal and with ileal pouch anal anastomosis for
ulcerative colitis. Colorectal Disease, 15: e323–e329.
296. Fazio VW, Kiran RP, Remzi FH, et al., (2013) Ileal pouch anal anastomosis: analysis of
outcome and quality of life in 3707 patients. Ann Surg; 257: 679–85.
297. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al.,
(1996) Predicting outcome in severe ulcer colitis. Gut;38:905–10.
298. Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP., (2009),
Long term outcome after admission for acute severe ulcerative colitis in Oxford: the 1990–
91 cohort. Inflamm Bowel Dis; 15: 823–828.
299. Arnaud Alves et al (2003) Subtotal colectomy for severe acute colitis: a 20-year
experience of a tertiary care center with an aggressive and early surgical policy JACS
197(3);379–385.
300. Börjesson, L., Willén, R., Haboubi, N., Duff, S. E. and Hultén, L. (2004), The risk of
dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for
ulcerative proctocolitis is low: A long-term term follow-up study. Colorectal Disease, 6: 494–
498.
301. Da Luz A, Kiran RP, Lavery I (2010) Clinical outcome of ileorectal anastomosis for
ulcerative colitis. Br J Surg 97:65–69.
302. Issa, Mazen, Knox, Josh F, Emmons, Jeanne, Bajaj, Jasmohan S, Binion, David G,
Vijayapal, Aravind, Graham, Mary Beth, Beaulieu, Dawn B, Otterson, Mary F, Lundeen,
Sarah, Skaros, Susan, Weber, Lydia R, Komorowski,Richard A. (2007). Impact of
Clostridium Difficile on inflammatory bowel disease. Clinical Gastroenterology and
Hepatology, 5(3), 345-351.
303. Daniela Jodorkovsky, Yuki Young, Maria T. Abreu, (2010), Clinical Outcomes of
Patients with Ulcerative Colitis and Co-existing Clostridium difficile Infection, Digestive
Diseases and Sciences, Volume 55, Issue 2, pp 415-420.
304. Domènech, Eugeni, Gassull, Miquel A, Vega, Roser, Ojanguren, Isabel, Hernández,
Águeda, Garcia-Planella, Esther, Bernal, Isabel, Rosinach, Mercè, Boix, Jaume,Cabré,
Eduard. (2008). Cytomegalovirus infection in ulcerative colitis: A prospective, comparative
study on prevalence and diagnostic strategy. Inflammatory Bowel Diseases, 14(10), 1373-
1379.
305. C. Soderberg-Naucler, (2006), Human cytomegalovirus persists in its host and attacks
and avoids elimination by the immune system, Critical Reviews in Immunology, vol. 26, no.
3, pp. 231–263.
306. Carne, P., & Frizelle, F. (2003). Cytomegalovirus and inflammatory bowel disease. The
New Zealand Medical Journal (Online), 116(1168), U306.
307. Akifumi Kuwabara, Haruhiko Okamoto, Takeyasu Suda, Yoichi Ajioka, Katsuyoshi
Hatakeyama, (2007),. Clinicopathologic characteristics of clinically relevant cytomegalovirus
infection in inflammatory bowel disease, Journal of Gastroenterology, Volume 42, Issue 10,
pp 823-829.
308. Kojima, Tetsu, Watanabe, Toshiaki, Hata, Keisuke, Shinozaki, Masaru, Yokoyama,
Tadashi,Nagawa, Hirokazu. (2006). Cytomegalovirus infection in ulcerative colitis.
Scandinavian Journal of Gastroenterology, 41(6), 706-711.
309. Cottone, M, Pagliaro, L, Pietrosi, G, Martorana, G, Casà, A, Pecoraro, G, Oliva, L,
Orlando, A, Rosselli, M,Rizzo, A. (2001). Prevalence of cytomegalovirus infection in severe
refractory ulcerative and crohn's colitis. American Journal of Gastroenterology, 96(3), 773-
775.
310. Hookey, L.C, Depew, W, Boag, A, Vanner,Stephen J. (2003). 6-mercaptopurine and
inflammatory bowel disease: Hidden ground for the cytomegalovirus. Canadian Journal of
311. Kandiel, Ahmed,Lashner, Bret. (2006). Cytomegalovirus colitis complicating
inflammatory bowel disease. American Journal of Gastroenterology, 101(12), 2857-2865.
312. Gómez-Reino, Juan,Carmona, Loreto. (2006). Recommendations to lower the risk of
tuberculosis in patients treated with tumour necrosis factor alpha antagonists. Acta
Reumatológica Portuguesa, 31(3), 201-203.
313. Gardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., &
Vinh, D. C. (2003). Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of
action and clinical management. The Lancet Infectious Diseases, 3(3), 148-55.
314. Wiesner, R. H., Grambsch, P. M., Dickson, E. R., Ludwig, J., Maccarty, R. L., Hunter,
E. B., Fleming, T. R., Fisher, L. D., Beaver, S. J. and Larusso, N. F. (1989), Primary
sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology,
10: 430–436.
315. Roy M. Soetikno, Otto S. Lin, Paul A. Heidenreich, Harvey S. Young, Michael O.
Blackstone, (2001), Increased risk of colorectal neoplasia in patients with primary sclerosing
cholangitis and ulcerative colitis: A meta-analysis, Gastrointestinal Endoscopy, Volume 56,
Issue 1, Pages 48–54.
316. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al.,
(2001), Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients
with Ulcerative Colitis and Primary Sclerosing Cholangitis. Ann Intern Med;134:89-95.
317. Wolf, J. M., Rybicki, L. A. and Lashner, B. A. (2005), The impact of ursodeoxycholic
acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing
cholangitis. Alimentary Pharmacology & Therapeutics, 22: 783–788.
318. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor K., (2003), Ursodeoxycholic acid
acts as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing
cholangitis. Gastroenterology 2003; 124: 889–93.
319. Eaden JA, Abrams KR, Mayberry JF., (2001), The risk of colorectal cancer in ulcerative
colitis: a meta-analysis. Gut. 2001;48:526-535.
320. Jess T, Loftus EV, Velayos FS, et al., (2006), Risk of intestinal cancer in inflammatory
bowel disease: a population-based study from Olmsted County, Minnesota.
Gastroenterology;130:1039-1046.
321. Rutter M, Saunders B, Wilkinsen K, et al., (2004), Severity of inflammation is a risk
factor for colorectal neoplasia in ulcerative colitis. Gastroenterology;126:451-459.
322. Rutter, Matthew D, Forbes, Alastair, Saunders, Brian P, Wilkinson, Kay H, Rumbles,
Steve, Schofield, Gillian, Kamm, Michael A, Williams, Christopher B, Price, Ashley B,
Talbot,Ian C. (2006). Thirty-year analysis of a colonoscopic surveillance program for
neoplasia in ulcerative colitis. Gastroenterology, 130(4), 1030-1038.
323. Fogt,F., Zhuang,Z., Poremba,C., Dockhorn-Dworniczak,B. and Vortmeyer,A. (1998)
Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated
dysplasia and carcinoma. Oncol. Rep., 5, 477–480.
324. Hussain,S.P., Amstad,P., Raja,K. et al. (2000) Increased p53 mutation load in
noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory
disease. Cancer Res., 60, 3333–3337.
325. Lashner,B.A., Shapiro,B.D., Husain,A. and Goldblum,J.R. (1999) Evaluation of the
usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis.
Am. J. Gastroenterol., 94, 456–462.
326. Rubin,C.E., Haggitt,R.C., Burmer,G.C., Brentnall,T.A., Stevens,A.C., Levine,D.S.,
Dean,P.J., Kimmey,M., Perera,D.R. and Rabinovitch,P.S. (1992) DNA aneuploidy in colonic
biopsies predicts future development of dysplasia in ulcerative colitis.
327. A. Roessnera, D. Kuestera, P. Malfertheinerb, R. Schneider-Stocka, (2008), Oxidative
stress in ulcerative colitis-associated carcinogenesis, Pathology - Research and Practice,
Volume 204, Issue 7, Pages 511–524.
328. Ullman TA, Loftus EV Jr, Kakar S, et al., (2002), The fate of low grade dysplasia in
ulcerative colitis. Am J Gastroenterol; 97:922.
329. Lim CH, Dixon MF, Vail A, et al., (2003), Ten year follow up of ulcerative colitis
patients with and without low grade dysplasia. Gut; 52:1127.
330. Shibahara, T., Miyazaki, K., Sato, D., Matsui, H., Yanaka, A., Nakahara, A. and Tanaka,
N. (2006), Rectal malignant lymphoma complicating ulcerative colitis treated with long-term
cyclosporine A. Journal of Gastroenterology and Hepatology, 21:336–338.
331. Greenstein, A.J, Mullin, G.E, Strauchen, J.A, Heimann, T, Janowitz, H.D, Aufses Jr,
A.H,Sachar, D.B. (1992). Lymphoma in inflammatory bowel disease. Cancer, 69(5), 1119-
1123.
332. Loftus Jr, Edward V, Tremaine, William J, Habermann, Thomas M, Harmsen, W. Scott,
Zinsmeister, Alan R, Sandborn,William J. (2000). Risk of lymphoma in inflammatory bowel
disease. American Journal of Gastroenterology, 95(9), 2308-2312.
333. Khan, S., Anderson, G. K., Eppstein, A. C., Eggenberger, J. C., & Margolin, D. A.
(2001). Ulcerative colitis and colonic lymphoma: A theoretical link. The American Surgeon,
67(7), 654-6.
334. Mowat C, Cole A, Windsor A, et al., (2011), Guidelines for the management of
inflammatory bowel disease in adults. Gut 2011; 60:571.
335. Turner D, Walsh CM, Steinhart AH, Griffiths AM., (2007), Response to corticosteroids
in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin
Gastroenterol Hepatol; 5:103.
336. Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas JL, et al., (2011) Successive
treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J
Gastroenterol.;106(4):771-7.
337. Ford, Alexander C, Sandborn, William J, Khan, Khurram J, Hanauer, Stephen B, Talley,
Nicholas J,Moayyedi, Paul. (2011). Efficacy of biological therapies in inflammatory bowel
disease: Systematic review and meta-analysis. American Journal of Gastroenterology, 106(4),
644-659.
338. Gheorghe C., Pascu O., Gheorghe L., Iacob R., Dumitru E., Tantau M., Vadan R.,
Goldis A., Balan G., Iacob S., Dobru D., Saftoiu A, (2004), Modern and Modulated
Therapeutical Solutions in Chronic Inflammatory Diseases, J Gastroenterol Hepatol.;
16(11):1153-9.
339. Gheorghe C., Pascu O., Iacob R. et al., (2003), Epidemiologic study of autoimmune
inflamatory bowel disease in Romanian adults, Romanian Journal of Gastroenterology;
12:57-59.
340. Baumgart DC (ed), (2012), Crohn’s Disease and Ulcerative Colitis: From Epidemiology
and Immunobiology to a Rational Diagnostic and Therapeutic Approach, Springer Science
Business Media.
341. Truelove, S.C,Witts, L.J. (1955). Cortisone in ulcerative colitis; final report on a
therapeutic trial. British Medical Journal, 2(4947), 1041-1048.
342. Moser, G. (2008). How often do patients with IBD have symptom recurrence?
Inflammatory Bowel Diseases, 14, S47-S47.
343. Bresci G, Parisi G, Bertoni M, Capria A, (2002), Long-term maintenance treatment in
ulcerative colitis: a 10-year follow-up, Digestive and Liver Disease, Volume 34, Issue 6,
Pages 419–423.
344. Melville, D. M., J. R. Jass, B. C. Morson, D. J. Pollock, P. I. Richman, N. A. Shepherd,
J. K. Ritchie, S. B. Love, and J. E. Lennard-Jones, (1989), Observer study of the grading of
dysplasia in ulcerative colitis: Comparison with clinical outcome. Human pathology 20, (10):
1008-1014.
345. Jass, J. R., J. England, and K. Miller. (1986). Value of mucin histochemistry in follow
up surveillance of patients with long standing ulcerative colitis. Journal of clinical pathology
39, (4): 393-398.
346. Theory and practice of histological techniques. (2008, 06). Scitech Book News, 32,
Churchill-Livingstone, London, England.
347. Yamagata, K., Tanaka, M. and Kudo, H. (1998), A quantitative immunohistochemical
evaluation of inflammatory cells at the affected and unaffected sites of inflammatory bowel
disease. Journal of Gastroenterology and Hepatology, 13: 801–808.
348. Miettinen, Markku. 2012. A simple method for generating multitissue blocks without
special equipment. Applied Immunohistochemistry and Molecular Morphology 20, (4): 410-
412.
349. Battifora, H., and P. Mehta. 1990. The checkerboard tissue block. an improved
multitissue control block. Laboratory Investigation 63, (5): 722-724.
350. Gillett, C. E., Springall, R. J., Barnes, D. M. and Hanby, A. M. (2000), Multiple tissue
core arrays in histopathology research: a validation study. J. Pathol., 192: 549–553.
351. Mengel, M., von Wasielewski, R., Wiese, B., Rüdiger, T., Müller-Hermelink, H. K. and
Kreipe, H. (2002), Inter-laboratory and inter-observer reproducibility of
immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J.
Pathol., 198: 292–299.
352. Micu, Gianina, Florica Stǎniceanu, Sabina Zurac, Alexandra Bastian, Eliza Gramadǎ,
Cristiana Popp, R. Andrei, et al. (2010). E-cadherin and beta-catenin expression in gastric
neoplastic and non-neoplastic lesions--correlations with H. pylori infection. Romanian
journal of internal medicine 48, (3): 271-280.
353. Ishii, Y., H. Koshiba, H. Ueno, I. Maeyama, and T. Takami. (1975). Characterization of
human B lymphocyte specific antigens. Journal of Immunology 114, (1).
354. Plevy, Scott, Bruce Salzberg, Gert Van Assche, Miguel Regueiro, Daniel Hommes,
William Sandborn, Stephen Hanauer, et al. (2007). A phase I study of visilizumab, a
humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
Gastroenterology 133, (5): 1414-1422.
355. Cohavy, Offer, and Stephan R. Targan. (2007). CD56 marks an effector T cell subset in
the human intestine. Journal of Immunology 178, (9): 5524-5532.
356. Ueno, Y., M. Sumii, Y. Miyanaka, M. Kanemoto, M. Morihara, M. Kunihiro, S. Tanaka,
and K. Chayama. (2003). Selective decrease in colonic cd56+T cells and cd161+T cells in the
inflamed mucosa of patients with ulcerative colitis. Gastroenterology 124, (4): A319-A319.
357. Caballero, T., F. Nogueras, M. T. Medina, M. D. Caracuel, C. De Sola, F. J. Martinez-
Salmeron, M. Rodrigo, and R. Garcia del Moral. (1995). Intraepithelial and lamina propria
leucocyte subsets in inflammatory bowel disease: An immunohistochemical study of colon
and rectal biopsy specimens. Journal of clinical pathology 48, (8): 743-748.
358. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG., (2000), CD7 delivers a pro-
apoptotic signal during galectin-1-induced T cell death. J Immunol; 165: 2331-2334.
359. Hildeman, David A., Thomas Mitchell, Bruce Aronowt, Sara Wojciechowski, John
Kappler, and Philippa Marrack. (2003). Control of bcl-2 expression by reactive oxygen
species. Proceedings of the National Academy of Sciences of the United States of America
100, (25): 15035-15040.
360. Johnson, M., D. Dimitrov, PJ Vojta, JC Barrett, A. Noda, Om Pereirasmith, and JR
Smith. 1994. Evidence For a p53-Independent Pathway For Up-Regulation of
SDI1/CIP1/WAF1/p21 RNA in Human-Cells. Molecular carcinogenesis 11, (2): 59-64.
361. Wong, N. A. C. S., Mayer, N. J., Anderson, C. E., Mckenzie, H. C., Morris, R. G.,
Diebold, J., Harrison, D. J. (2003). Cyclin D1 and p21 WAF1/CIP1 in ulcerative colitis-
related inflammation and epithelial neoplasia: A study of aberrant expression and underlying
mechanisms. Human Pathology, 34(6), 580-8.
362. Del Zotto, B., Mumolo, G., Pronio, A. M., Montesani, C., Tersigni, R. and Boirivant, M.
(2003), TGF-β1 production in inflammatory bowel disease: differing production patterns in
Crohn's disease and ulcerative colitis. Clinical & Experimental Immunology, 134: 120–126.
363. Welton M, Lehman R, Warren R, Bunnett N. Human colonic endothelial cells express
vascular endothelial growth factor (VEGF) and its receptors. Gastroenterology.
1997;112(4):A1200-.
364. Gheorghe C., Pascu O., Gheorghe L., Iacob R., Dumitru E., Tantau M., Vadan R.,
Goldis A., Balan G., Iacob S., Dobru D., Saftoiu A., (2004), Epidemiology of inflammatory
bowel disease în adults who refer to gastroenterology care în Romania: a multi centre study.
Eur J Gastroenterol Hepatol.; 16(11):1153-9.
365. Vendrell, Roberto, Venegas, Heidi L, Pérez, Cynthia M, Morell, Carlos, Roman, Ruth
V, Torres,Esther A. (2013). Differences in prevalence of inflammatory bowel disease in
puerto rico between commercial and government-sponsored managed health care insured
individuals. Boletín De La Asociación Médica De Puerto Rico, 105(2), 15-19.
366. Niv, Yaron, Abuksis, Galia, Fraser,Gerald M. (2000). Epidemiology of ulcerative colitis
in israel: A survey of israeli kibbutz settlements. American Journal of Gastroenterology,
95(3), 693-698.
367. Loftus, C. G., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Tremaine, W. J.,
Melton, L. J. and Sandborn, W. J. (2007), Update on the incidence and prevalence of Crohn's
disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel
Dis, 13: 254–261.
368. Lee, J. H., Cheon, J. H., Moon, C. M., Park, J. J., Hong, S. P., Kim, T. I., & Kim, W. H.
(2010). Do patients with ulcerative colitis diagnosed at a young age have more severe disease
activity than patients diagnosed when older? Digestion, 81(4), 237-43.
369. Stasikowska-Kanicka, O., Danilewicz, M., Glowacka, A., & Wagrowska-Danilewicz,
M. (2012). Mast cells and eosinophils are involved in activation of ulcerative colitis.
Advances in Medical Sciences, 57(2), 230.
370. Powell N, Walker MM, Talley NJ. (2010), Gastrointestinal eosinophils in health, disease
and functional disorders. Nat Rev Gastroenterol Hepatol.;7(3):146-56.
371. Wedemeyer J, Vosskuhl K., (2008), Role of gastrointestinal eosinophils in inflammatory
bowel disease and intestinal tumours. Best Pract Res Clin Gastroenterol.;22(3):537 49.372.
372. Naito, Yuji, Takagi, Tomohisa,Yoshikawa, Toshikazu. (2007). Neutrophil-dependent
oxidative stress in ulcerative colitis. Journal of Clinical Biochemistry and Nutrition, 41(1),
18-26.
373. Melson, Joshua E, Giusto, Deborah, Kwasny, Mary, Eichenseer, Peter, Jakate, Shriram,
Keshavarzian, Ali. (2010). Histopathology predictors of medically refractory ulcerative
colitis. Diseases of the Colon and Rectum, 53(9), 1280-1286.
374. Hockenbery, David M., Zoltan N. Oltvai, Xiao-Ming Yin, Curt L. Milliman, and Stanley
J. Korsmeyer. (1993), Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell
75, (2): 241-251.
375. Shteingart, S., M. Rapoport, I. Grodzovski, O. Sabag, M. Lichtenstein, R. Eavri, and H.
Lorberboum-Galski. 2009. Therapeutic potency of IL2-caspase 3 targeted treatment in a
murine experimental model of inflammatory bowel disease. Gut 58, (6): 790-798.
376. Hockenbery, David M, Zutter, Mary, Hickey, William, Nahm, Moon, Korsmeyer,
Stanley J. (1991). BCL2 protein is topographically restricted in tissues characterized by
apoptotic cell death. Proceedings of the National Academy of Sciences of the United States
of America, 88(16), 6961-6965.
377. T.O. Frommel, E.J. Zarling, (1999), Chronic inflammation and cancer: potential role of
Bcl-2 gene family members as regulators of cellular antioxidant status, Med. Hypotheses, 52
pp. 27–30.
378. Kinra SLP, Mehta CA, Rai LGR., (2005), Study of p53 and bcl-2 Oncoproteins in
Ulcerative Colitis with Dysplasia. MJAFI;2:125-129.
379. Rogler, G. (2014). Chronic ulcerative colitis and colorectal cancer. Cancer Letters,
345(2), 235-241.
380. Mitsuhashi, J., Mikami, T., Saigenji, K. and Okayasu, I. (2005), Significant correlation
of morphological remodeling in ulcerative colitis with disease duration and between elevated
p53 and p21WAF1 expression in rectal mucosa and neoplastic development. Pathology
International, 55: 113–121.
381. Daniela S. Ardelean, Melissa Yin, Mirjana Jerkic, Madonna Peter, Bo Ngan, Robert S.
Kerbel, F. Stuart Foster, Michelle Letarte, (2014), Anti-VEGF therapy reduces intestinal
inflammation in Endoglin heterozygous mice subjected to experimental colitis. Angiogenesis,
Volume 17, Issue 3, pp 641-659.
382. Bousvaros A, Leichtner A, Zurakowski D, Kwon J, Law T, Ke ough K, Fishman S,
(1999), Elevated serum vascular endothelial growth factor in children and young adults with
Crohn’s disease. Dig Dis Sci 44(2):424–43.
383. Coriat, Romain, Olivier Mir, Sarah Leblanc, Stanislas Ropert, Catherine Brezault,
Stanislas Chaussade, and François Goldwasser. (2011). Feasibility of anti-VEGF agent
bevacizumab in patients with crohn's disease. Inflammatory bowel diseases 17, (7): 1632-
1632.
384. D.T. Shima, U. Deutsch, P.A. D'Amore, (1995), Hypoxic induction of vascular
endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in
mRNA stability FEBS Lett., 370 (3) pp. 203–208.
385. Stadnicki A, Mechnik G, Klimacka-Nawrot E, Wolanska-Karut A, Labuzek K. (2009).
Transforming growth factor-β1 and its receptors in patients with ulcerative colitis. Int
Immunopharmacol 9: 761–766.
386. Mäkitalo, Laura, Kaija-Leena Kolho, Riitta Karikoski, Hannele Anthoni, and Ulpu
Saarialho-Kere. (2010). Expression profiles of matrix metalloproteinases and their inhibitors
in colonic inflammation related to pediatric inflammatory bowel disease. Scandinavian
Journal of Gastroenterology 45, (7-8): 862-871.
387. Emma Pirilä, Nungavarm S. Ramamurthy, Timo Sorsa, Tuula Salo, Jarkko Hietanen,
Päivi Maisi, (2003), Gelatinase A (MMP-2), Collagenase-2 (MMP-8), and Laminin-5 γ2-
Chain Expression in Murine Inflammatory Bowel Disease (Ulcerative Colitis), Digestive
Diseases and Sciences, Volume 48, Issue 1, pp 93-98.
388. Gisbert, J. P. and Chaparro, M. (2014), Systematic review with meta-analysis:
inflammatory bowel disease in the elderly. Alimentary Pharmacology & Therapeutics, 39:
459–477.
389. Katz, Seymour, and Richard Feldstein. 2008. Inflammatory bowel disease of the elderly:
A wake-up call. Gastroenterology and Hepatology 4, (5): 337-347.
390. Shivananda S, Lennard-Jones J, Logan RFA, et al. (1996) Incidence of inflammatory
bowel disease across Europe: is there a difference between north and south? Results of the
European collaborative study on inflammatory bowel disease (EC-IBD). Gut 39:690–697.
391. Moum B, Ekbom A, Vatn MH, et al. (1997) Inflammatory bowel disease: re-evaluation
of the diagnosis in a prospective population based study in south eastern Norway. Gut
40:328–332.
392. Richter, J. M., Kushkuley, S., Barrett, J. A. and Oster, G. (2012), Treatment of new-
onset ulcerative colitis and ulcerative proctitis: a retrospective study. Alimentary
Pharmacology & Therapeutics, 36: 248–256.
393. Topical 5-ASA most effective for ulcerative colitis and ulcerative proctitis. (2000).
Journal of Pharmacy Technology, 16(4), 161.
394. Cohen, Russell D, Woseth, Douglas M, Thisted, Ronald A, Hanauer,Stephen B. (2000).
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative
colitis and ulcerative proctitis. American Journal of Gastroenterology, 95(5), 1263-1276.
395. Bouguen, G., Roblin, X., Bourreille, A., Feier, L., Filippi, J., Nancey, S., Bretagne, J.-F.,
Flourié, B., Hébuterne, X., Bigard, M.-A., Siproudhis, L. and Peyrin-Biroulet, L. (2010),
Infliximab for refractory ulcerative proctitis. Alimentary Pharmacology & Therapeutics, 31:
1178–1185.
396. Lewis, James D, Chuai, Shaokun, Nessel, Lisa, Lichtenstein, Gary R, Aberra, Faten N,
Ellenberg,Jonas H. (2008). Use of the noninvasive components of the Mayo score to assess
clinical response in ulcerative colitis. Inflammatory Bowel Diseases, 14(12), 1660-1666.
397. Keyashian, K., BL Surma, JT Williams, RD Cohen, IM Hanan, LH Raffals, SB
Hanauer, and DT Rubin. 2012. Interobserver and intraobserver agreement of the mayo score
of endoscopic activity in ulcerative colitis. Gastroenterology 142, (5): S660-S660.
398. Rosenberg L, Nanda KS, Zenlea T et al., (2013), Histologic markers of inflammation in
patients with ulcerative colitis in clinical remission. Clin. Gastroenterol. Hepatol. 11(8), 991–
996.
399. Miheller, P., Mandel, M. D., Mullner, K., & Lakatos, P. L. (2013). Clinical aspects of
mucosal healing in inflammatory bowel diseases: What is it and what is the real value for the
everyday practice? Expert Review of Clinical Immunology, 9(9), 871-82.
400. Lemmens; Bart, Arijs, Ingrid, Van Assche, Gert, Sagaert, Xavier, Geboes, Karel,
Ferrante, Marc, Rutgeerts, Paul, Vermeire, Séverine,De Hertogh, Gert. (2013). Correlation
between the endoscopic and histologic score in assessing the activity of ulcerative colitis.
Inflammatory Bowel Diseases, 19(6), 1194-1201.
401. Jena, Gopabandhu, Trivedi, Priyanka Pushkarbhai,Sandala, Balanarsimha. (2012).
Oxidative stress in ulcerative colitis: An old concept but a new concern. Free Radical
Research, 46(11), 1339-1345.
402. Makiyama, K, Kanzaki, S, Yamasaki, K, Zeairiarte, W,Tsuji, Y. (1995). Activation of
Eosinophils in the Pathophysiology of Ulcerative-Colitis. Journal of Gastroenterology, 30,
64-69.
403. Piazuelo, M. B., Camargo, M. C., Mera, R. M., Delgado, A. G., Peek, R. M., Jr., Correa,
H., Correa, P. (2008). Eosinophils and mast cells in chronic gastritis: Possible implications in
carcinogenesis. Human Pathology, 39(9), 1360-9.
404. Atkins, D., & Furuta, G. T. (2010). Mucosal immunology, eosinophilic esophagitis, and
other intestinal inflammatory diseases. Journal of Allergy and Clinical Immunology, 125(2),
S255-S261.
405. Banki, Farzaneh, DeMeester, Steven R, Abate, Emmanuele, Lipham, John C,
Chandrasoma, Parakrama, Crookes, Peter F, DeMeester, Tom R, Flanagan, Patrick, Zehetner,
Joerg, Armstrong, Analisa, Hagen, Jeffrey A, Joshi, Amit, Sinha, Raina, Oh, Daniel,Oezcelik,
Arzu. (2010). Progressive mucosal injury in patients with gastroesophageal reflux disease and
increasing peripheral blood eosinophil counts. Archives of Surgery, 145(4), 363-366.
406. Jain, M., Kasetty, S., Sudheendra, U. S., Tijare, M., Khan, S., & Desai, A. (2014).
Assessment of tissue eosinophilia as a prognosticator in oral epithelial dysplasia and oral
squamous cell carcinoma--an image analysis study. Pathology Research International.
407. D'Arienzo, A, Mazzacca, G, Manguso, F, Bennato, R, Scaglione, G, Vicinanza, G,
Astarita, C, D'Armiento, FP, Scarpa, R,Gargano, D. (2000). Allergic diseases and the
mucosal eosinophil infiltrate in ulcerative colitis. Gastroenterology, 118(4), A312-A312.
408. Schumacher, G., B. Kollberg, and B. Sandstedt. 1994. A prospective study of first
attacks of inflammatory bowel disease and infectious colitis. histologic course during the 1st
year after presentation. Scandinavian Journal of Gastroenterology 29, (4): 318-332.
409. Katz, Seymour,M.D., M.A.C.G. (2013). My treatment approach to the management of
ulcerative colitis. Mayo Clinic Proceedings, 88(8), 841-53.
410. Manzano, L, Alvarez-Mon, M, Abreu, L, Vargas, J. Antonio, De La Morena, E,
Corugedo, F,Duràntez, A. (1992). Functional impairment of natural killer cells in active
ulcerative colitis: Reversion of the defective natural killer activity by interleukin 2. Gut,
33(2), 246-251.
411. Tamura, J, Jinbo, T, Itoh, K, Take, H, Matsushima, T, Murakami, H, Kubota, K,
Tsuchiya, J, Naruse, T. (1994). Suppressed Natural-Killer-Cell Activity In Ulcerative-Colitis.
Journal of Medicine, 25(5), 337-340.
412. Bezzio, C, Furfaro, F, de Franchis, R, Maconi, G, Asthana, AK,Ardizzone, S. (2014).
Ulcerative colitis: Current pharmacotherapy and future directions. Expert Opinion on
Pharmacotherapy, 15(12), 1659-1670.
413. Murphy, Michael, Fullen, Doug, Carlson,J.Andrew. (2002). Low CD7 expression in
benign and malignant cutaneous lymphocytic infiltrates: Experience with an antibody
reactive with paraffin-embedded tissue. American Journal of Dermatopathology, 24(1), 6-16.
414. Cotta, Ana Cristina, Cintra, Maria Letícia, De Souza, Elemir MacEdo, Chagas, Cristiano
Aparecido, Magna, Luis Alberto, Fleury, Raul Negrão, Brousset, Pierre, Vassallo, José.
(2006). Diagnosis of mycosis fungoides: A comparative immunohistochemical study of T-
cell markers using a novel anti-CD7 antibody. Applied Immunohistochemistry and Molecular
Morphology, 14(3), 291-295.
415. Sergei I. Grivennikov, (2013), Inflammation and colorectal cancer: colitis-associated
neoplasia, Seminars in Immunopathology, Volume 35, Issue 2, pp 229-244.
416. Niederau, Claus, Frank Backmerhoff, Brigitte Schumacher, and Christoph Niederau.
1997. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and
ulcerative colitis. Hepato-gastroenterology 44, (13): 90-107.
417. Torsney E, Charlton R, Parums D, Collis M, Arthur HM (2002) Inducible expression of
human endoglin during inflammation and wound healing in vivo. Inflamm Res 51(9):464–
470.
418. Martin, Gary R., Catherine M. Keenan, Keith A. Sharkey, and Frank R. Jirik. 2011.
Endogenous prion protein attenuates experimentally induced colitis. American Journal of
Pathology 179, (5): 2290-2301.
419. Beck, PL, Xavier, RJ, Rosenberg, IR,Podolsky, DK. (2000). Intestinal epithelial cell
expression of TGFB dominant negative receptor II (DNRII) results in decreased wound
healing in vitro and increased susceptibility to colonic injury in vivo. Gastroenterology,
118(4), A872-A872.
420. Bauer, J., Liebisch, G., Hofmann, C., Huy, C., Schmitz, G., Obermeier, F., & Bock, J.
(2009). Lipid alterations in experimental murine colitis: Role of ceramide and imipramine for
matrix metalloproteinase-1 expression. PLoS One, 4(9).
421. Wang YD, Mao JW (2007) Expression of matrix metalloproteinase-1 and tumor necrosis
factor-alpha in ulcerative colitis. World J Gastroenterol 13: 5926-5932.
422. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Hommes DW, et al.
(2007) Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor
necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.
World J Gastroenterol 13: 2960-2966.
423. Faubion, WA, Higgins, PD, Harris, JM, Diehl, L, Wright, L, Tew, GW, Luca, D, Basu,
K, Keir, ME, Fletcher, JG, O'Byrne, S, Feagan, BG, de Villiers, WJS, Salzberg, B, Plevy, S,
Proctor, DD,Valentine, JF. (2013). EMerging BiomARKers in inflammatory bowel disease
(EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel
combination of biomarkers for Crohn's disease activity: Role of cross-sectional imaging.
American Journal OF Gastroenterology, 108(12), 1891-1900.
424. Yamagata, M., Mikami, T., Tsuruta, T., Yokoyama, K., Sada, M., Kobayashi, K.,
Okayasu, I. (2011). Submucosal fibrosis and basic-fibroblast growth factor-positive
neutrophils correlate with colonic stenosis in cases of ulcerative colitis. Digestion, 84(1), 12-
21.)
425. Sato, A. and Machinami, R. (1999), p53 immunohistochemistry of ulcerative colitis-
associated with dysplasia and carcinoma. Pathology International, 49: 858–868.
426. Christophi, George P., Rong Rong, Philip G. Holtzapple, Paul T. Massa, and Steve K.
Landas. 2012. Immune markers and differential signaling networks in ulcerative colitis and
Crohn's disease. Inflammatory bowel diseases 18, (12): 2342-2356.
427. Wong, N. A. C. S. and Harrison, D. J. (2001), Colorectal neoplasia in ulcerative
colitis—recent advances. Histopathology, 39: 221–234.
428. Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L. (2010), Cytomegalovirus
infection in patients with active inflammatory bowel disease. Dig Dis Sci.;55:1059–1065.
429. The European (ECCO) Consensus on infection in IBD: what does it change for the
clinician? Gut, 58 (10) (2009), pp. 1313–1315.

Bibliografie 2

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Bibliografie 2

Uploaded by

Copyright:

Available Formats

Referinţe

You might also like